Additional Information
Book Details
Abstract
The #1 IV drug handbook for 40 years, Intravenous Medications: A Handbook for Nurses and Health Professionals is trusted for its accuracy and comprehensive coverage. Whether you prefer the portable print version or the convenient electronic format, this new edition provides essential data on administering more than 350 intravenous (IV) drugs, entries for new IV drugs recently approved by the FDA, hundreds of new drug facts, a detailed index of generic and trade names and more — all alphabetically organized to help you find drug information quickly and easily.
- UNIQUE! Published annually to ensure you have essential information on the most recently approved IV drugs as well as updated information on existing drugs.
- UNIQUE! Contains thorough coverage of more than 350 IV drugs — supplying you with far more than any other comparable handbook.
- UNIQUE! Time-tested page layout keep all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page.
- Consistent, easy-to-use format provides all the essential clinical information you need on IV drug administration.
- Lists IV drugs alphabetically by generic name for quick clinical reference.
- Updated IV drug dilution and dosage charts within monographs provide quick access to essential information.
- Special sections highlight dosage variances for geriatric, pediatric, infant, and neonatal patients.
- Black Box Warnings, screening, and highlighting make locating key information quick and easy.
- Printed thumb tabs help you find information faster.
"A companion website at http://evolve.elsevier.com/IVMeds/ provides alerts, monographs for selected agents not included in the book, a step-by-step tutorial for calculating IV drug dosages, IV drug dosage calculators, interactive IV drug dosage examples, printable general dilution and solution compatibility charts, and more."
- NEW! Four new drug monographs provide you with current, clinically relevant drug information for new IV drugs recently approved by the FDA.
- NEW! Updated drug monographs reflect the latest changes in IV drug therapy.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front cover | Cover | ||
| How to use | ifc | ||
| How to use | i | ||
| How to use this book | iii | ||
| Step 1 | iii | ||
| Step 2 | iii | ||
| That’s it! | iii | ||
| Develop the “look it up” habit. | iii | ||
| Front matter | v | ||
| Copyright | vi | ||
| Reviewers | vii | ||
| Nursing and pharmacology consultants | vii | ||
| Dedication | ix | ||
| Preface | xi | ||
| Format and content of intravenous medications | xvii | ||
| Compatibilities | xviii | ||
| Rate of administration: | xix | ||
| Actions: | xix | ||
| Indications and uses: | xix | ||
| Contraindications: | xix | ||
| Precautions: | xix | ||
| Monitor: | xx | ||
| Patient education: | xx | ||
| Maternal/child: | xx | ||
| Elderly: | xx | ||
| Drug/lab interactions: | xx | ||
| Side effects: | xx | ||
| Post-marketing: | xx | ||
| Antidote: | xx | ||
| Key to abbreviations | xxi | ||
| Important IV therapy facts | xxiii | ||
| Usual dose | xxiii | ||
| Dilution | xxiii | ||
| Incompatibilities | xxiv | ||
| Techniques | xxiv | ||
| Rate of administration | xxiv | ||
| Patient education | xxiv | ||
| Side effects | xxiv | ||
| Resources | xxv | ||
| Publications | xxv | ||
| Website resources | xxv | ||
| A | 1 | ||
| Abatacept | 1 | ||
| Usual dose | 1 | ||
| Pediatric dose | 1 | ||
| Dose adjustments | 1 | ||
| Dilution | 1 | ||
| Compatibility | 2 | ||
| Rate of administration | 2 | ||
| Actions | 2 | ||
| Indications and uses | 2 | ||
| Contraindications | 2 | ||
| Precautions | 2 | ||
| Drug/lab interactions | 3 | ||
| Side effects | 3 | ||
| Antidote | 3 | ||
| Abciximab | 4 | ||
| Usual dose | 4 | ||
| Dilution | 5 | ||
| Compatibility | 5 | ||
| Rate of administration | 5 | ||
| Actions | 5 | ||
| Indications and uses | 6 | ||
| Contraindications | 6 | ||
| Precautions | 6 | ||
| Drug/lab interactions | 7 | ||
| Side effects | 7 | ||
| Antidote | 8 | ||
| Acetaminophen | 8 | ||
| Usual dose | 8 | ||
| Pediatric dose | 8 | ||
| Dose adjustments | 9 | ||
| Dilution | 9 | ||
| Compatibility | 9 | ||
| Rate of administration | 9 | ||
| Actions | 9 | ||
| Indications and uses | 9 | ||
| Contraindications | 9 | ||
| Precautions | 9 | ||
| Drug/lab interactions | 10 | ||
| Side effects | 10 | ||
| Antidote | 10 | ||
| Acetazolamide sodium | 10 | ||
| Usual dose | 10 | ||
| Pediatric dose | 11 | ||
| Dose adjustments | 11 | ||
| Dilution | 11 | ||
| Compatibility (underline indicates conflicting compatibility information) | 11 | ||
| Rate of administration | 11 | ||
| Actions | 11 | ||
| Indications and uses | 11 | ||
| Contraindications | 11 | ||
| Precautions | 11 | ||
| Drug/lab interactions | 12 | ||
| Side effects | 12 | ||
| Antidote | 12 | ||
| Acetylcysteine injection | 12 | ||
| Usual dose | 12 | ||
| Dose adjustments | 13 | ||
| Dilution | 13 | ||
| Compatibility | 14 | ||
| Rate of administration | 14 | ||
| Actions | 14 | ||
| Indications and uses | 14 | ||
| Contraindications | 14 | ||
| Precautions | 14 | ||
| Drug/lab interactions | 15 | ||
| Side effects | 15 | ||
| Antidote | 16 | ||
| Acyclovir | 16 | ||
| Usual dose | 16 | ||
| Pediatric dose | 16 | ||
| Neonatal dose | 16 | ||
| Dose adjustments | 16 | ||
| Dilution | 17 | ||
| Compatibility (underline indicates conflicting compatibility information) | 17 | ||
| Rate of administration | 18 | ||
| Actions | 18 | ||
| Indications and uses | 18 | ||
| Contraindications | 18 | ||
| Precautions | 18 | ||
| Drug/lab interactions | 19 | ||
| Side effects | 19 | ||
| Antidote | 19 | ||
| Adenosine | 20 | ||
| Usual dose | 20 | ||
| Pediatric dose | 20 | ||
| Dose adjustments | 20 | ||
| Dilution | 20 | ||
| Compatibility | 20 | ||
| Rate of administration | 21 | ||
| Actions | 21 | ||
| Indications and uses | 21 | ||
| Contraindications | 21 | ||
| Precautions | 21 | ||
| Drug/lab interactions | 22 | ||
| Side effects | 23 | ||
| Antidote | 23 | ||
| Ado-trastuzumab emtansine | 24 | ||
| Usual dose | 24 | ||
| Dose adjustments | 24 | ||
| Dilution | 25 | ||
| Compatibility | 26 | ||
| Rate of administration | 26 | ||
| Actions | 26 | ||
| Indications and uses | 26 | ||
| Contraindications | 26 | ||
| Precautions | 26 | ||
| Drug/lab interactions | 27 | ||
| Side effects | 27 | ||
| Antidote | 28 | ||
| Albumin (human) | 29 | ||
| Usual dose | 29 | ||
| Pediatric dose | 29 | ||
| Dilution | 30 | ||
| Compatibility | 30 | ||
| Rate of administration | 30 | ||
| Actions | 30 | ||
| Indications and uses | 30 | ||
| Contraindications | 31 | ||
| Precautions | 31 | ||
| Drug/lab interactions | 31 | ||
| Side effects | 31 | ||
| Antidote | 31 | ||
| Aldesleukin | 32 | ||
| Usual dose (international units [IU]) | 32 | ||
| Dose adjustments | 32 | ||
| Dilution (international units [IU]) | 33 | ||
| Compatibility (underline indicates conflicting compatibility information) | 33 | ||
| Rate of administration | 34 | ||
| Actions | 34 | ||
| Indications and uses | 34 | ||
| Contraindications | 34 | ||
| Precautions | 35 | ||
| Drug/lab interactions | 37 | ||
| Side effects | 37 | ||
| Antidote | 38 | ||
| Alemtuzumab | 39 | ||
| Usual dose | 39 | ||
| Dose adjustments | 39 | ||
| Dilution | 40 | ||
| Compatibility | 40 | ||
| Rate of administration | 40 | ||
| Actions | 40 | ||
| Indications and uses | 40 | ||
| Contraindications | 41 | ||
| Precautions | 41 | ||
| Drug/lab interactions | 41 | ||
| Side effects | 42 | ||
| Antidote | 42 | ||
| Alfentanil hydrochloride | 42 | ||
| Usual dose | 42 | ||
| Pediatric dose | 43 | ||
| Dose adjustments | 43 | ||
| Dilution | 44 | ||
| Compatibility | 44 | ||
| Rate of administration | 44 | ||
| Actions | 44 | ||
| Indications and uses | 44 | ||
| Contraindications | 44 | ||
| Precautions | 44 | ||
| Drug/lab interactions | 45 | ||
| Side effects | 46 | ||
| Antidote | 46 | ||
| Allopurinol sodium | 47 | ||
| Usual dose | 47 | ||
| Pediatric dose | 47 | ||
| Dose adjustments | 47 | ||
| Dilution | 47 | ||
| Compatibility | 47 | ||
| Rate of administration | 48 | ||
| Actions | 48 | ||
| Indications and uses | 48 | ||
| Contraindications | 48 | ||
| Precautions | 48 | ||
| Drug/lab interactions | 49 | ||
| Side effects | 49 | ||
| Antidote | 49 | ||
| Alpha1-proteinase inhibitor (human) | 50 | ||
| Usual dose | 50 | ||
| Dilution | 50 | ||
| Compatibility | 51 | ||
| Rate of administration | 51 | ||
| Actions | 51 | ||
| Indications and uses | 51 | ||
| Contraindications | 51 | ||
| Precautions | 51 | ||
| Drug/lab interactions | 52 | ||
| Side effects | 52 | ||
| Antidote | 52 | ||
| Alprostadil | 53 | ||
| Usual dose | 53 | ||
| Dilution | 53 | ||
| Compatibility | 53 | ||
| Rate of administration | 53 | ||
| Actions | 53 | ||
| Indications and uses | 53 | ||
| Contraindications | 53 | ||
| Precautions | 54 | ||
| Drug/lab interactions | 54 | ||
| Side effects | 54 | ||
| Antidote | 54 | ||
| Alteplase, recombinant | 54 | ||
| Usual dose | 54 | ||
| Acute myocardial infarction | 54 | ||
| Accelerated infusion; weight greater than 67 kg: | 55 | ||
| Accelerated infusion; weight equal to or less than 67 kg: | 55 | ||
| 3-hour infusion; weight 65 kg or greater: | 55 | ||
| 3-hour infusion; weight less than 65 kg: | 55 | ||
| Acute ischemic stroke | 55 | ||
| Pulmonary embolism | 55 | ||
| Central venous access device (CVAD) occlusions, cathflo activase | 55 | ||
| Patient weight 30 kg or greater: | 55 | ||
| Patient weight less than 30 kg: | 55 | ||
| Dilution | 55 | ||
| Compatibility | 56 | ||
| Rate of administration | 56 | ||
| Actions | 56 | ||
| Indications and uses | 57 | ||
| Contraindications | 57 | ||
| Precautions | 57 | ||
| Drug/lab interactions | 60 | ||
| Side effects | 60 | ||
| Antidote | 60 | ||
| Amifostine | 62 | ||
| Usual dose | 62 | ||
| Prophylactic reduction of cisplatin-induced nephrotoxicity, prophylactic reduction of cisplatin induced–neurotoxicity (u ... | 62 | ||
| B | 156 | ||
| Basiliximab | 156 | ||
| Usual dose | 156 | ||
| Pediatric dose | 156 | ||
| Dose adjustments | 156 | ||
| Dilution | 156 | ||
| Compatibility | 156 | ||
| Rate of administration | 156 | ||
| Actions | 157 | ||
| Indications and uses | 157 | ||
| Contraindications | 157 | ||
| Precautions | 157 | ||
| Drug/lab interactions | 158 | ||
| Side effects | 158 | ||
| Antidote | 158 | ||
| Belatacept | 158 | ||
| Usual dose | 158 | ||
| Dose adjustments | 159 | ||
| Dilution | 159 | ||
| Compatibility | 160 | ||
| Rate of administration | 160 | ||
| Actions | 160 | ||
| Indications and uses | 160 | ||
| Contraindications | 160 | ||
| Precautions | 160 | ||
| Drug/lab interactions | 161 | ||
| Side effects | 162 | ||
| Antidote | 162 | ||
| Belimumab | 162 | ||
| Usual dose | 162 | ||
| Dilution | 162 | ||
| Compatibility | 163 | ||
| Rate of administration | 163 | ||
| Actions | 163 | ||
| Indications and uses | 163 | ||
| Contraindications | 163 | ||
| Precautions | 163 | ||
| Drug/lab interactions | 164 | ||
| Side effects | 164 | ||
| Antidote | 164 | ||
| Bendamustine hydrochloride | 165 | ||
| Usual dose | 165 | ||
| Dose adjustments | 165 | ||
| Dilution | 165 | ||
| Compatibility | 165 | ||
| Rate of administration | 165 | ||
| Actions | 166 | ||
| Indications and uses | 166 | ||
| Contraindications | 166 | ||
| Precautions | 166 | ||
| Drug/lab interactions | 167 | ||
| Side effects | 167 | ||
| Antidote | 168 | ||
| Bevacizumab | 168 | ||
| Usual dose | 168 | ||
| Dose adjustments | 168 | ||
| Dilution | 169 | ||
| Compatibility | 169 | ||
| Rate of administration | 169 | ||
| Actions | 169 | ||
| Indications and uses | 169 | ||
| Contraindications | 170 | ||
| Precautions | 170 | ||
| Drug/lab interactions | 171 | ||
| Side effects | 171 | ||
| Antidote | 172 | ||
| Bivalirudin | 173 | ||
| Usual dose | 173 | ||
| Dose adjustments | 173 | ||
| Dilution | 173 | ||
| Compatibility (underline indicates conflicting compatibility information) | 174 | ||
| Rate of administration | 174 | ||
| Actions | 175 | ||
| Indications and uses | 175 | ||
| Contraindications | 175 | ||
| Precautions | 175 | ||
| Drug/lab interactions | 176 | ||
| Side effects | 176 | ||
| Antidote | 176 | ||
| Bleomycin sulfate | 177 | ||
| Usual dose | 177 | ||
| Dose adjustments | 177 | ||
| Dilution | 177 | ||
| Compatibility | 177 | ||
| Rate of administration | 178 | ||
| Actions | 178 | ||
| Indications and uses | 178 | ||
| Contraindications | 178 | ||
| Precautions | 178 | ||
| Drug/lab interactions | 179 | ||
| Side effects | 179 | ||
| Antidote | 179 | ||
| Bortezomib | 180 | ||
| Usual dose | 180 | ||
| Dose adjustments | 180 | ||
| Dilution | 182 | ||
| Compatibility | 182 | ||
| Rate of administration | 182 | ||
| Actions | 182 | ||
| Indications | 182 | ||
| Contraindications | 182 | ||
| Precautions | 183 | ||
| Drug/lab interactions | 184 | ||
| Side effects | 185 | ||
| Antidote | 185 | ||
| Botulism immune globulin (intravenous human) | 186 | ||
| Pediatric dose | 186 | ||
| Dilution | 186 | ||
| Compatibility | 186 | ||
| Rate of administration | 186 | ||
| Actions | 186 | ||
| Indications and uses | 187 | ||
| Contraindications | 187 | ||
| Precautions | 187 | ||
| Drug/lab interactions | 187 | ||
| Side effects | 187 | ||
| Antidote | 188 | ||
| Brentuximab vedotin | 188 | ||
| Usual dose | 188 | ||
| Dose adjustments | 188 | ||
| Dilution | 188 | ||
| Compatibility | 189 | ||
| Rate of administration | 189 | ||
| Actions | 189 | ||
| Indications and uses | 189 | ||
| Contraindications | 189 | ||
| Precautions | 189 | ||
| Drug/lab interactions | 190 | ||
| Side effects | 190 | ||
| Antidote | 190 | ||
| Bumetanide | 191 | ||
| Usual dose | 191 | ||
| Dose adjustments | 191 | ||
| Dilution | 191 | ||
| Compatibility (underline indicates conflicting compatibility information) | 191 | ||
| Rate of administration | 191 | ||
| Actions | 191 | ||
| Indications and uses | 191 | ||
| Contraindications | 191 | ||
| Precautions | 191 | ||
| Drug/lab interactions | 192 | ||
| Side effects | 192 | ||
| Antidote | 193 | ||
| Buprenorphine hydrochloride | 193 | ||
| Usual dose | 193 | ||
| Pediatric dose | 193 | ||
| Dose adjustments | 193 | ||
| Dilution | 193 | ||
| Compatibility | 193 | ||
| Rate of administration | 194 | ||
| Actions | 194 | ||
| Indications and uses | 194 | ||
| Contraindications | 194 | ||
| Precautions | 194 | ||
| Drug/lab interactions | 194 | ||
| Side effects | 195 | ||
| Antidote | 195 | ||
| Busulfan | 195 | ||
| Usual dose | 195 | ||
| Pediatric dose | 195 | ||
| Dose adjustments | 195 | ||
| Dilution | 195 | ||
| Compatibility | 196 | ||
| Rate of administration | 196 | ||
| Actions | 196 | ||
| Indications and uses | 196 | ||
| Contraindications | 196 | ||
| Precautions | 196 | ||
| Drug/lab interactions | 197 | ||
| Side effects | 197 | ||
| Antidote | 198 | ||
| Butorphanol tartrate | 198 | ||
| Usual dose | 198 | ||
| Dose adjustments | 198 | ||
| Dilution | 199 | ||
| Compatibility | 199 | ||
| Rate of administration | 199 | ||
| Actions | 199 | ||
| Indications and uses | 199 | ||
| Contraindications | 199 | ||
| Precautions | 199 | ||
| Drug/lab interactions | 200 | ||
| Side effects | 200 | ||
| Antidote | 200 | ||
| C | 201 | ||
| C1 esterase inhibitor (human) | 201 | ||
| Usual dose | 201 | ||
| Dilution | 201 | ||
| Compatibility | 201 | ||
| Rate of administration | 201 | ||
| Actions | 201 | ||
| Indications and uses | 201 | ||
| Contraindications | 202 | ||
| Precautions | 202 | ||
| Drug/lab interactions | 202 | ||
| Side effects | 202 | ||
| Antidote | 202 | ||
| C1 inhibitor (human) | 203 | ||
| Usual dose | 203 | ||
| Dilution (international units [IU]) | 203 | ||
| Compatibility | 203 | ||
| Rate of administration | 203 | ||
| Actions | 203 | ||
| Indications and uses | 203 | ||
| Contraindications | 203 | ||
| Precautions | 203 | ||
| Drug/lab interactions | 204 | ||
| Side effects | 204 | ||
| Antidote | 204 | ||
| Cabazitaxel | 205 | ||
| Usual dose | 205 | ||
| Dose adjustments | 205 | ||
| Dilution | 205 | ||
| Compatibility | 206 | ||
| Rate of administration | 206 | ||
| Actions | 206 | ||
| Indications and uses | 206 | ||
| Contraindications | 206 | ||
| Precautions | 206 | ||
| Drug/lab interactions | 207 | ||
| Side effects | 207 | ||
| Antidote | 208 | ||
| Caffeine citrate | 208 | ||
| Pediatric dose | 208 | ||
| Dose adjustments | 208 | ||
| Dilution | 208 | ||
| Compatibility | 209 | ||
| Rate of administration | 209 | ||
| Actions | 209 | ||
| Indications and uses | 209 | ||
| Contraindications | 209 | ||
| Precautions | 209 | ||
| Drug/lab interactions | 210 | ||
| Side effects | 210 | ||
| Antidote | 210 | ||
| Calcitriol | 211 | ||
| Usual dose | 211 | ||
| Pediatric dose | 211 | ||
| Dose adjustments | 211 | ||
| Dilution | 211 | ||
| Compatibility | 211 | ||
| Rate of administration | 212 | ||
| Actions | 212 | ||
| Indications and uses | 212 | ||
| Contraindications | 212 | ||
| Precautions | 212 | ||
| Drug/lab interactions | 213 | ||
| Side effects | 213 | ||
| Antidote | 213 | ||
| Calcium chloride | 214 | ||
| Usual dose | 214 | ||
| Pediatric dose | 214 | ||
| Dilution | 214 | ||
| Compatibility (underline indicates conflicting compatibility information) | 214 | ||
| Rate of administration | 215 | ||
| Actions | 215 | ||
| Indications and uses | 215 | ||
| Contraindications | 215 | ||
| Precautions | 215 | ||
| Drug/lab interactions | 215 | ||
| Side effects | 216 | ||
| Antidote | 216 | ||
| Calcium gluconate | 216 | ||
| Usual dose | 216 | ||
| Pediatric dose | 216 | ||
| Neonatal dose | 217 | ||
| Dilution | 217 | ||
| Compatibility (underline indicates conflicting compatibility information) | 217 | ||
| Rate of administration | 217 | ||
| Actions | 217 | ||
| Indications and uses | 218 | ||
| Contraindications | 218 | ||
| Precautions | 218 | ||
| Drug/lab interactions | 218 | ||
| Side effects | 218 | ||
| Antidote | 218 | ||
| Capreomycin | 219 | ||
| Usual dose | 219 | ||
| Dose adjustments | 219 | ||
| Dilution | 219 | ||
| Compatibility | 219 | ||
| Rate of administration | 219 | ||
| Actions | 220 | ||
| Indications and uses | 220 | ||
| Contraindications | 220 | ||
| Precautions | 220 | ||
| Drug/lab interactions | 221 | ||
| Side effects | 221 | ||
| Antidote | 221 | ||
| Carboplatin | 222 | ||
| Usual dose | 222 | ||
| Dose adjustments | 222 | ||
| Dilution | 222 | ||
| Compatibility (underline indicates conflicting compatibility information) | 223 | ||
| Rate of administration | 223 | ||
| Actions | 223 | ||
| Indications and uses | 223 | ||
| Contraindications | 223 | ||
| Precautions | 223 | ||
| Drug/lab interactions | 224 | ||
| Side effects | 225 | ||
| Antidote | 225 | ||
| Carfilzomib | 226 | ||
| Usual dose | 226 | ||
| Dose adjustments | 226 | ||
| Dilution | 228 | ||
| Compatibility | 228 | ||
| Rate of administration | 228 | ||
| Actions | 228 | ||
| Indications and uses | 228 | ||
| Contraindications | 228 | ||
| Precautions | 228 | ||
| Drug/lab interactions | 229 | ||
| Side effects | 229 | ||
| Antidote | 229 | ||
| Carmustine (BCNU) | 230 | ||
| Usual dose | 230 | ||
| Dose adjustments | 230 | ||
| Dilution | 230 | ||
| Compatibility | 231 | ||
| Rate of administration | 231 | ||
| Actions | 231 | ||
| Indications and uses | 231 | ||
| Contraindications | 231 | ||
| Precautions | 231 | ||
| Drug/lab interactions | 232 | ||
| Side effects | 232 | ||
| Antidote | 232 | ||
| Caspofungin acetate | 233 | ||
| Usual dose | 233 | ||
| Pediatric dose | 233 | ||
| Dose adjustments | 233 | ||
| Dilution | 234 | ||
| Compatibility (underline indicates conflicting compatibility information) | 234 | ||
| Rate of administration | 234 | ||
| Actions | 234 | ||
| Indications and uses | 235 | ||
| Contraindications | 235 | ||
| Precautions | 235 | ||
| Drug/lab interactions | 235 | ||
| Side effects | 236 | ||
| Antidote | 236 | ||
| Cefazolin sodium | 237 | ||
| Usual dose | 237 | ||
| Pediatric dose | 237 | ||
| Neonatal dose | 237 | ||
| Dose adjustments | 237 | ||
| Dilution | 238 | ||
| Compatibility (underline indicates conflicting compatibility information) | 238 | ||
| Rate of administration | 238 | ||
| Actions | 238 | ||
| Indications and uses | 238 | ||
| Contraindications | 239 | ||
| Precautions | 239 | ||
| Drug/lab interactions | 239 | ||
| Side effects | 239 | ||
| Antidote | 240 | ||
| Cefepime hydrochloride | 240 | ||
| Usual dose | 240 | ||
| Pediatric dose | 241 | ||
| Dose adjustments | 241 | ||
| Dilution | 241 | ||
| Compatibility (underline indicates conflicting compatibility information) | 242 | ||
| Rate of administration | 243 | ||
| Actions | 243 | ||
| Indications and uses | 243 | ||
| Contraindications | 243 | ||
| Precautions | 243 | ||
| Drug/lab interactions | 244 | ||
| Side effects | 244 | ||
| Antidote | 245 | ||
| Cefotaxime sodium | 246 | ||
| Usual dose | 246 | ||
| Pediatric dose | 246 | ||
| Dose adjustments | 246 | ||
| Dilution | 246 | ||
| Compatibility (underline indicates conflicting compatibility information) | 246 | ||
| Rate of administration | 247 | ||
| Actions | 247 | ||
| Indications and uses | 247 | ||
| Contraindications | 247 | ||
| Precautions | 247 | ||
| Drug/lab interactions | 248 | ||
| Side effects | 248 | ||
| Antidote | 249 | ||
| Cefoxitin sodium | 250 | ||
| Usual dose | 250 | ||
| Pediatric dose | 250 | ||
| Neonatal dose | 250 | ||
| Dose adjustments | 250 | ||
| Dilution | 251 | ||
| Compatibility (underline indicates conflicting compatibility information) | 251 | ||
| Rate of administration | 251 | ||
| Actions | 251 | ||
| Indications and uses | 252 | ||
| Contraindications | 252 | ||
| Precautions | 252 | ||
| Drug/lab interactions | 252 | ||
| Side effects | 253 | ||
| Antidote | 253 | ||
| Ceftaroline fosamil | 254 | ||
| Usual dose | 254 | ||
| Dose adjustments | 254 | ||
| Dilution | 254 | ||
| Compatibility (underline indicates conflicting compatibility information) | 255 | ||
| Rate of administration | 255 | ||
| Actions | 255 | ||
| Indications and uses | 255 | ||
| Contraindications | 255 | ||
| Precautions | 255 | ||
| Drug/lab interactions | 256 | ||
| Side effects | 256 | ||
| Antidote | 256 | ||
| Ceftazidime | 257 | ||
| Usual dose | 257 | ||
| Pediatric dose | 257 | ||
| Neonatal dose | 257 | ||
| Dose adjustments | 257 | ||
| Dilution | 258 | ||
| Compatibility (underline indicates conflicting compatibility information) | 258 | ||
| Rate of administration | 258 | ||
| Actions | 258 | ||
| Indications and uses | 259 | ||
| Contraindications | 259 | ||
| Precautions | 259 | ||
| Drug/lab interactions | 259 | ||
| Side effects | 260 | ||
| Antidote | 260 | ||
| Ceftriaxone sodium | 260 | ||
| Usual dose | 260 | ||
| Pediatric dose | 261 | ||
| Neonatal dose | 261 | ||
| Dose adjustments | 261 | ||
| Dilution | 261 | ||
| Compatibility (underline indicates conflicting compatibility information) | 262 | ||
| Rate of administration | 262 | ||
| Actions | 262 | ||
| Indications and uses | 262 | ||
| Contraindications | 263 | ||
| Precautions | 263 | ||
| Drug/lab interactions | 264 | ||
| Side effects | 264 | ||
| Antidote | 264 | ||
| Cefuroxime sodium | 265 | ||
| Usual dose | 265 | ||
| Pediatric dose | 265 | ||
| Neonatal dose | 265 | ||
| Dose adjustments | 265 | ||
| Dilution | 265 | ||
| Compatibility (underline indicates conflicting compatibility information) | 266 | ||
| Rate of administration | 266 | ||
| Actions | 266 | ||
| Indications and uses | 266 | ||
| Contraindications | 266 | ||
| Precautions | 266 | ||
| Drug/lab interactions | 267 | ||
| Side effects | 267 | ||
| Antidote | 268 | ||
| Centruroides (scorpion) immune F(ab’)2 (equine) injection | 268 | ||
| Usual dose | 268 | ||
| Pediatric dose | 268 | ||
| Dilution | 268 | ||
| Compatibility | 269 | ||
| Rate of administration | 269 | ||
| Actions | 269 | ||
| Indications and uses | 269 | ||
| Contraindications | 269 | ||
| Precautions | 269 | ||
| Drug/lab interactions | 269 | ||
| Side effects | 269 | ||
| Antidote | 270 | ||
| Cetuximab | 270 | ||
| Usual dose | 270 | ||
| Dose adjustments | 270 | ||
| Dilution | 271 | ||
| Compatibility | 271 | ||
| Rate of administration | 271 | ||
| Actions | 271 | ||
| Indications and uses | 272 | ||
| Contraindications | 272 | ||
| Precautions | 272 | ||
| Drug/lab interactions | 273 | ||
| Side effects | 273 | ||
| Antidote | 274 | ||
| Chloramphenicol sodium succinate | 274 | ||
| Usual dose | 274 | ||
| Neonatal dose | 274 | ||
| Dose adjustments | 274 | ||
| Dilution | 275 | ||
| Compatibility (underline indicates conflicting compatibility information) | 275 | ||
| Rate of administration | 275 | ||
| Actions | 275 | ||
| Indications and uses | 275 | ||
| Contraindications | 275 | ||
| Precautions | 275 | ||
| Drug/lab interactions | 276 | ||
| Side effects | 276 | ||
| Antidote | 277 | ||
| Chlorpromazine hydrochloride | 277 | ||
| Usual dose | 277 | ||
| Pediatric dose | 277 | ||
| Dose adjustments | 277 | ||
| Dilution | 277 | ||
| Compatibility (underline indicates conflicting compatibility information) | 278 | ||
| Rate of administration | 278 | ||
| Actions | 278 | ||
| Indications and uses | 278 | ||
| Contraindications | 278 | ||
| Precautions | 278 | ||
| Drug/lab interactions | 279 | ||
| Side effects | 280 | ||
| Antidote | 280 | ||
| Cidofovir injection | 281 | ||
| Usual dose | 281 | ||
| Dose adjustments | 281 | ||
| Dilution | 281 | ||
| Compatibility | 281 | ||
| Rate of administration | 282 | ||
| Actions | 282 | ||
| Indications and uses | 282 | ||
| Contraindications | 282 | ||
| Precautions | 282 | ||
| Drug/lab interactions | 283 | ||
| Side effects | 283 | ||
| Antidote | 284 | ||
| Ciprofloxacin | 284 | ||
| Usual dose | 284 | ||
| Pediatric dose | 285 | ||
| Dose adjustments | 285 | ||
| Dilution | 285 | ||
| Compatibility (underline indicates conflicting compatibility information) | 285 | ||
| Rate of administration | 286 | ||
| Actions | 286 | ||
| Indications and uses | 286 | ||
| Contraindications | 286 | ||
| Precautions | 286 | ||
| Drug/lab interactions | 288 | ||
| Side effects | 289 | ||
| Antidote | 289 | ||
| Cisatracurium besylate | 290 | ||
| Usual dose | 290 | ||
| Adjunct to propofol/N2O/O2 anesthesia for adults (IV bolus) | 290 | ||
| D | 334 | ||
| Dacarbazine | 334 | ||
| Usual dose | 334 | ||
| Dose adjustments | 334 | ||
| Dilution | 334 | ||
| Compatibility (underline indicates conflicting compatibility information) | 334 | ||
| Rate of administration | 334 | ||
| Actions | 334 | ||
| Indications and uses | 334 | ||
| Contraindications | 334 | ||
| Precautions | 334 | ||
| Drug/lab interactions | 335 | ||
| Side effects | 335 | ||
| Antidote | 335 | ||
| Dactinomycin | 336 | ||
| Usual dose | 336 | ||
| Pediatric dose | 336 | ||
| Dose adjustments | 336 | ||
| Dilution | 336 | ||
| Compatibility | 336 | ||
| Rate of administration | 337 | ||
| Actions | 337 | ||
| Indications and uses | 337 | ||
| Contraindications | 337 | ||
| Precautions | 337 | ||
| Drug/lab interactions | 338 | ||
| Side effects | 338 | ||
| Antidote | 338 | ||
| Dantrolene sodium | 339 | ||
| Usual dose | 339 | ||
| Pediatric dose | 339 | ||
| Dose adjustments | 339 | ||
| Dilution | 339 | ||
| Compatibility | 339 | ||
| Rate of administration | 339 | ||
| Actions | 339 | ||
| Indications and uses | 339 | ||
| Contraindications | 340 | ||
| Precautions | 340 | ||
| Drug/lab interactions | 340 | ||
| Side effects | 340 | ||
| Antidote | 340 | ||
| Daptomycin | 341 | ||
| Usual dose | 341 | ||
| Dose adjustments | 341 | ||
| Dilution | 341 | ||
| Compatibility (underline indicates conflicting compatibility information) | 341 | ||
| Rate of administration | 341 | ||
| Actions | 342 | ||
| Indications and uses | 342 | ||
| Limitation of use: | 342 | ||
| Contraindications | 342 | ||
| Precautions | 342 | ||
| Drug/lab interactions | 343 | ||
| Side effects | 343 | ||
| Antidote | 344 | ||
| Darbepoetin alfa | 344 | ||
| Usual dose | 344 | ||
| Dose adjustments | 345 | ||
| Dilution | 346 | ||
| Compatibility | 346 | ||
| Rate of administration | 346 | ||
| Actions | 346 | ||
| Indications and uses | 347 | ||
| Contraindications | 347 | ||
| Precautions | 347 | ||
| Drug/lab interactions | 349 | ||
| Side effects | 349 | ||
| Antidote | 349 | ||
| Daunorubicin hydrochloride daunorubicin citrate liposomal injection | 350 | ||
| Usual dose | 350 | ||
| E | 440 | ||
| Eculizumab | 440 | ||
| Usual dose | 440 | ||
| Pediatric dose | 440 | ||
| Dose adjustments | 441 | ||
| Dilution | 441 | ||
| Compatibility | 441 | ||
| Rate of administration | 441 | ||
| Actions | 442 | ||
| Indications and uses | 442 | ||
| Contraindications | 442 | ||
| Precautions | 442 | ||
| Drug/lab interactions | 444 | ||
| Side effects | 444 | ||
| Antidote | 444 | ||
| Edetate calcium disodium | 445 | ||
| Usual dose | 445 | ||
| Dose adjustments | 445 | ||
| Dilution | 445 | ||
| Compatibility | 445 | ||
| Rate of administration | 445 | ||
| Actions | 445 | ||
| Indications and uses | 446 | ||
| Contraindications | 446 | ||
| Precautions | 446 | ||
| Drug/lab interactions | 446 | ||
| Side effects | 447 | ||
| Antidote | 447 | ||
| Edetate disodium | 447 | ||
| Usual dose | 447 | ||
| Pediatric dose | 447 | ||
| Dose adjustments | 447 | ||
| Dilution | 447 | ||
| Compatibility | 447 | ||
| Rate of administration | 447 | ||
| Actions | 447 | ||
| Indications and uses | 448 | ||
| Contraindications | 448 | ||
| Precautions | 448 | ||
| Drug/lab interactions | 448 | ||
| Side effects | 448 | ||
| Antidote | 448 | ||
| Edrophonium chloride | 449 | ||
| Usual dose | 449 | ||
| Pediatric dose | 449 | ||
| Dose adjustments | 449 | ||
| Dilution | 449 | ||
| Compatibility | 449 | ||
| Rate of administration | 450 | ||
| Actions | 450 | ||
| Indications and uses | 450 | ||
| Contraindications | 450 | ||
| Precautions | 450 | ||
| Drug/lab interactions | 450 | ||
| Side effects | 450 | ||
| Antidote | 451 | ||
| Edrophonium chloride and atropine sulfate | 451 | ||
| Usual dose | 451 | ||
| Dose adjustments | 451 | ||
| Dilution | 451 | ||
| Compatibility | 451 | ||
| Rate of administration | 451 | ||
| Actions | 451 | ||
| Indications and uses | 452 | ||
| Contraindications | 452 | ||
| Precautions | 452 | ||
| Drug/lab interactions | 452 | ||
| Side effects | 452 | ||
| Antidote | 453 | ||
| Enalaprilat | 453 | ||
| Usual dose | 453 | ||
| Pediatric dose | 453 | ||
| Dose adjustments | 453 | ||
| Dilution | 453 | ||
| Compatibility (underline indicates conflicting compatibility information) | 453 | ||
| Rate of administration | 454 | ||
| Actions | 454 | ||
| Indications and uses | 454 | ||
| Contraindications | 454 | ||
| Precautions | 454 | ||
| Drug/lab interactions | 455 | ||
| Side effects | 455 | ||
| Antidote | 455 | ||
| Epinephrine hydrochloride | 456 | ||
| Usual dose | 456 | ||
| Pediatric dose | 456 | ||
| Dose adjustments | 457 | ||
| Dilution | 457 | ||
| Compatibility (underline indicates conflicting compatibility information) | 457 | ||
| Rate of administration | 458 | ||
| Actions | 458 | ||
| Indications and uses | 458 | ||
| Contraindications | 458 | ||
| Precautions | 458 | ||
| Drug/lab interactions | 459 | ||
| Side effects | 459 | ||
| Antidote | 459 | ||
| Epirubicin hydrochloride | 460 | ||
| Usual dose | 460 | ||
| Ellence | 460 | ||
| Pharmorubicin PFS | 460 | ||
| Metastatic breast cancer: | 460 | ||
| F | 504 | ||
| Factor IX (human) • factor IX complex (human) | 504 | ||
| Usual dose (international units [IU]) | 504 | ||
| All formulations | 504 | ||
| Minor hemorrhage: | 504 | ||
| Major trauma or surgery: | 504 | ||
| Dental extraction: | 504 | ||
| Prophylaxis: | 504 | ||
| Factor IX complex | 504 | ||
| Reversal of coumarin effect: | 504 | ||
| Dilution | 504 | ||
| Compatibility | 505 | ||
| Rate of administration | 505 | ||
| Actions | 505 | ||
| Indications and uses | 505 | ||
| Contraindications | 505 | ||
| Precautions | 505 | ||
| Drug/lab interactions | 506 | ||
| Side effects | 506 | ||
| Antidote | 506 | ||
| Factor IX (recombinant) | 507 | ||
| Usual dose (international units [IU]) | 507 | ||
| Dilution | 507 | ||
| Compatibility | 508 | ||
| Rate of administration | 508 | ||
| Actions | 508 | ||
| Indications and uses | 508 | ||
| Contraindications | 508 | ||
| Precautions | 508 | ||
| Drug/lab interactions | 508 | ||
| Side effects | 509 | ||
| Antidote | 509 | ||
| Factor XIII concentrate (human) | 509 | ||
| Usual dose (international units [IU]) | 509 | ||
| Dose adjustments | 509 | ||
| Dilution | 509 | ||
| Compatibility | 510 | ||
| Rate of administration | 510 | ||
| Actions | 510 | ||
| Indications and uses | 510 | ||
| Contraindications | 510 | ||
| Precautions | 510 | ||
| Drug/lab interactions | 511 | ||
| Side effects | 511 | ||
| Antidote | 511 | ||
| Famotidine | 512 | ||
| Usual dose | 512 | ||
| Pediatric dose | 512 | ||
| Dose adjustments | 512 | ||
| Dilution | 512 | ||
| Compatibility (underline indicates conflicting compatibility information) | 512 | ||
| Rate of administration | 513 | ||
| Actions | 513 | ||
| Indications and uses | 513 | ||
| Contraindications | 513 | ||
| Precautions | 513 | ||
| Drug/lab interactions | 513 | ||
| Side effects | 514 | ||
| Antidote | 514 | ||
| Fat emulsion, intravenous * | 514 | ||
| Usual dose | 514 | ||
| Pediatric dose | 514 | ||
| Dose adjustments | 514 | ||
| Dilution | 514 | ||
| Compatibility (underline indicates conflicting compatibility information) | 515 | ||
| Rate of administration | 515 | ||
| Actions | 516 | ||
| Indications and uses | 516 | ||
| Contraindications | 516 | ||
| Precautions | 516 | ||
| Drug/lab interactions | 516 | ||
| Side effects | 516 | ||
| Antidote | 517 | ||
| Fenoldopam mesylate | 517 | ||
| Usual dose | 517 | ||
| Pediatric dose | 517 | ||
| Dose adjustments | 517 | ||
| Dilution | 518 | ||
| Compatibility (underline indicates conflicting compatibility information) | 518 | ||
| Rate of administration | 518 | ||
| Actions | 520 | ||
| Indications and uses | 520 | ||
| Contraindications | 520 | ||
| Precautions | 520 | ||
| Drug/lab interactions | 521 | ||
| Side effects | 521 | ||
| Antidote | 521 | ||
| Fentanyl citrate | 522 | ||
| Usual dose | 522 | ||
| Pediatric dose | 522 | ||
| Dose adjustments | 522 | ||
| Dilution | 522 | ||
| Compatibility (underline indicates conflicting compatibility information) | 522 | ||
| Rate of administration | 523 | ||
| Actions | 523 | ||
| Indications and uses | 523 | ||
| Contraindications | 523 | ||
| Precautions | 523 | ||
| Drug/lab interactions | 524 | ||
| Side effects | 524 | ||
| Antidote | 524 | ||
| Ferumoxytol | 525 | ||
| Usual dose | 525 | ||
| Dose adjustments | 525 | ||
| Dilution | 525 | ||
| Compatibility | 525 | ||
| Rate of administration | 525 | ||
| Actions | 525 | ||
| Indications and uses | 525 | ||
| Contraindications | 525 | ||
| Precautions | 525 | ||
| Drug/lab interactions | 526 | ||
| Side effects | 526 | ||
| Antidote | 526 | ||
| Fibrinogen concentrate (human) | 527 | ||
| Usual dose | 527 | ||
| Dilution | 527 | ||
| Compatibility | 527 | ||
| Rate of administration | 527 | ||
| Actions | 527 | ||
| Indications and uses | 527 | ||
| Contraindications | 527 | ||
| Precautions | 527 | ||
| Drug/lab interactions | 528 | ||
| Side effects | 528 | ||
| Antidote | 528 | ||
| Filgrastim | 529 | ||
| Usual dose | 529 | ||
| Dose adjustments | 529 | ||
| Dilution | 530 | ||
| Compatibility (underline indicates conflicting compatibility information) | 530 | ||
| Rate of administration | 530 | ||
| Actions | 530 | ||
| Indications and uses | 531 | ||
| Contraindications | 531 | ||
| Precautions | 531 | ||
| Drug/lab interactions | 532 | ||
| Side effects | 532 | ||
| Antidote | 532 | ||
| Fluconazole | 533 | ||
| Usual dose | 533 | ||
| Pediatric dose | 533 | ||
| Neonatal dose | 533 | ||
| Dose adjustments | 533 | ||
| Dilution | 534 | ||
| Compatibility (underline indicates conflicting compatibility information) | 534 | ||
| Rate of administration | 534 | ||
| Actions | 534 | ||
| Indications and uses | 535 | ||
| Contraindications | 535 | ||
| Precautions | 535 | ||
| Drug/lab interactions | 535 | ||
| Side effects | 536 | ||
| Antidote | 537 | ||
| Fludarabine phosphate | 537 | ||
| Usual dose | 537 | ||
| Pediatric dose | 537 | ||
| Dose adjustments | 537 | ||
| Dilution | 537 | ||
| Compatibility | 538 | ||
| Rate of administration | 538 | ||
| Actions | 538 | ||
| Indications and uses | 538 | ||
| Contraindications | 538 | ||
| Precautions | 539 | ||
| Drug/lab interactions | 540 | ||
| Side effects | 540 | ||
| Antidote | 540 | ||
| Flumazenil | 541 | ||
| Usual dose | 541 | ||
| Pediatric dose | 541 | ||
| Dose adjustments | 541 | ||
| Dilution | 541 | ||
| Compatibility | 541 | ||
| Rate of administration | 541 | ||
| Actions | 542 | ||
| Indications and uses | 542 | ||
| Contraindications | 542 | ||
| Precautions | 542 | ||
| Drug/lab interactions | 543 | ||
| Side effects | 543 | ||
| Antidote | 544 | ||
| Fluorouracil | 544 | ||
| Usual dose | 544 | ||
| Dose adjustments | 545 | ||
| Dilution | 545 | ||
| Compatibility (underline indicates conflicting compatibility information) | 545 | ||
| Rate of administration | 545 | ||
| Actions | 545 | ||
| Indications and uses | 546 | ||
| Contraindications | 546 | ||
| Precautions | 546 | ||
| Drug/lab interactions | 546 | ||
| Side effects | 546 | ||
| Antidote | 547 | ||
| Folic acid | 547 | ||
| Usual dose | 547 | ||
| Pediatric dose | 547 | ||
| Dose adjustments | 547 | ||
| Dilution | 547 | ||
| Compatibility | 548 | ||
| Rate of administration | 548 | ||
| Actions | 548 | ||
| Indications and uses | 548 | ||
| Contraindications | 548 | ||
| Precautions | 548 | ||
| Drug/lab interactions | 548 | ||
| Side effects | 548 | ||
| Antidote | 548 | ||
| Fomepizole injection | 549 | ||
| Usual dose | 549 | ||
| Dose adjustments | 549 | ||
| Dilution | 549 | ||
| Compatibility | 550 | ||
| Rate of administration | 550 | ||
| Actions | 550 | ||
| Indications and uses | 550 | ||
| Contraindications | 550 | ||
| Precautions | 550 | ||
| Drug/lab interactions | 551 | ||
| Side effects | 551 | ||
| Antidote | 551 | ||
| Fosaprepitant dimeglumine | 552 | ||
| Usual dose | 552 | ||
| Dose adjustments | 553 | ||
| Dilution | 553 | ||
| Compatibility | 553 | ||
| Rate of administration | 553 | ||
| Actions | 553 | ||
| Indications and uses | 553 | ||
| Contraindications | 554 | ||
| Precautions | 554 | ||
| Drug/lab interactions | 554 | ||
| Side effects | 555 | ||
| Antidote | 555 | ||
| Foscarnet sodium | 556 | ||
| Usual dose | 556 | ||
| Dose adjustments | 556 | ||
| Dilution | 557 | ||
| Compatibility (underline indicates conflicting compatibility information) | 557 | ||
| Rate of administration | 557 | ||
| Actions | 558 | ||
| Indications and uses | 558 | ||
| Contraindications | 558 | ||
| Precautions | 558 | ||
| Drug/lab interactions | 559 | ||
| Side effects | 559 | ||
| Antidote | 560 | ||
| Fosphenytoin sodium | 561 | ||
| Usual dose | 561 | ||
| Pediatric dose | 561 | ||
| Dose adjustments | 561 | ||
| Dilution | 561 | ||
| Compatibility | 561 | ||
| Rate of administration | 561 | ||
| Actions | 562 | ||
| Indications and uses | 562 | ||
| Contraindications | 562 | ||
| Precautions | 562 | ||
| Drug/lab interactions | 564 | ||
| Side effects | 565 | ||
| Antidote | 565 | ||
| Fospropofol disodium | 566 | ||
| Usual dose | 566 | ||
| Dose adjustments | 567 | ||
| Dilution | 567 | ||
| Compatibility | 567 | ||
| Rate of administration | 567 | ||
| Actions | 567 | ||
| Indications and uses | 568 | ||
| Contraindications | 568 | ||
| Precautions | 568 | ||
| Drug/lab interactions | 569 | ||
| Side effects | 569 | ||
| Antidote | 569 | ||
| Furosemide | 570 | ||
| Usual dose | 570 | ||
| Pediatric dose | 570 | ||
| Neonatal dose | 570 | ||
| Dose adjustments | 570 | ||
| Dilution | 570 | ||
| Compatibility (underline indicates conflicting compatibility information) | 570 | ||
| Rate of administration | 571 | ||
| Actions | 571 | ||
| Indications and uses | 571 | ||
| Contraindications | 571 | ||
| Precautions | 571 | ||
| Drug/lab interactions | 572 | ||
| Side effects | 573 | ||
| Antidote | 573 | ||
| G | 574 | ||
| Ganciclovir sodium | 574 | ||
| Usual dose | 574 | ||
| Pediatric dose | 574 | ||
| Dose adjustments | 574 | ||
| Dilution | 575 | ||
| Compatibility (underline indicates conflicting compatibility information) | 575 | ||
| Rate of administration | 575 | ||
| Actions | 575 | ||
| Indications and uses | 576 | ||
| Contraindications | 576 | ||
| Precautions | 576 | ||
| Drug/lab interactions | 577 | ||
| Side effects | 577 | ||
| Antidote | 577 | ||
| Gemcitabine hydrochloride | 578 | ||
| Usual dose | 578 | ||
| Dose adjustments | 578 | ||
| Dilution | 579 | ||
| Compatibility (underline indicates conflicting compatibility information) | 580 | ||
| Rate of administration | 580 | ||
| Actions | 580 | ||
| Indications and uses | 580 | ||
| Contraindications | 581 | ||
| Precautions | 581 | ||
| Drug/lab interactions | 582 | ||
| Side effects | 582 | ||
| Antidote | 583 | ||
| Gentamicin sulfate | 584 | ||
| Usual dose | 584 | ||
| Pediatric dose | 584 | ||
| Neonatal dose | 584 | ||
| Dose adjustments | 584 | ||
| Dilution | 585 | ||
| Compatibility (underline indicates conflicting compatibility information) | 585 | ||
| Rate of administration | 586 | ||
| Actions | 586 | ||
| Indications and uses | 586 | ||
| Contraindications | 586 | ||
| Precautions | 587 | ||
| Drug/lab interactions | 587 | ||
| Side effects | 588 | ||
| Antidote | 588 | ||
| Glucagon (rDNA origin) | 589 | ||
| Usual dose | 589 | ||
| Pediatric dose | 589 | ||
| Dose adjustments | 589 | ||
| Dilution | 589 | ||
| Compatibility | 589 | ||
| Rate of administration | 590 | ||
| Actions | 590 | ||
| Indications and uses | 590 | ||
| Contraindications | 590 | ||
| Precautions | 590 | ||
| Drug/lab interactions | 591 | ||
| Side effects | 591 | ||
| Antidote | 591 | ||
| Glucarpidase | 592 | ||
| Usual dose | 592 | ||
| Pediatric dose | 592 | ||
| Dose adjustments | 592 | ||
| Dilution | 592 | ||
| Compatibility | 592 | ||
| Rate of administration | 592 | ||
| Actions | 592 | ||
| Indications and uses | 592 | ||
| Contraindications | 592 | ||
| Precautions | 593 | ||
| Drug/lab interactions | 593 | ||
| Side effects | 593 | ||
| Antidote | 593 | ||
| Glycopyrrolate | 594 | ||
| Usual dose | 594 | ||
| Pediatric dose | 594 | ||
| Dose adjustments | 594 | ||
| Dilution | 594 | ||
| Compatibility (underline indicates conflicting compatibility information) | 595 | ||
| Rate of administration | 595 | ||
| Actions | 595 | ||
| Indications and uses | 595 | ||
| Contraindications | 595 | ||
| Precautions | 595 | ||
| Drug/lab interactions | 596 | ||
| Side effects | 596 | ||
| Antidote | 596 | ||
| Granisetron hydrochloride | 597 | ||
| Usual dose | 597 | ||
| Pediatric dose | 597 | ||
| Dose adjustments | 597 | ||
| Dilution | 597 | ||
| Compatibility (underline indicates conflicting compatibility information) | 597 | ||
| Rate of administration | 598 | ||
| Actions | 598 | ||
| Indications and uses | 598 | ||
| Contraindications | 598 | ||
| Precautions | 598 | ||
| Drug/lab interactions | 599 | ||
| Side effects | 599 | ||
| Antidote | 599 | ||
| H | 600 | ||
| Hemin | 600 | ||
| Usual dose | 600 | ||
| Dilution | 600 | ||
| Compatibility | 600 | ||
| Rate of administration | 600 | ||
| Actions | 600 | ||
| Indications and uses | 600 | ||
| Contraindications | 600 | ||
| Precautions | 600 | ||
| Drug/lab interactions | 600 | ||
| Side effects | 601 | ||
| Antidote | 601 | ||
| Heparin sodium | 601 | ||
| Usual dose | 601 | ||
| Pediatric dose | 602 | ||
| Dose adjustments | 602 | ||
| Dilution | 602 | ||
| Compatibility (underline indicates conflicting compatibility information) | 603 | ||
| Rate of administration | 604 | ||
| Actions | 604 | ||
| Indications and uses | 604 | ||
| Contraindications | 604 | ||
| Precautions | 604 | ||
| Drug/lab interactions | 606 | ||
| Side effects | 606 | ||
| Antidote | 606 | ||
| Hepatitis B immune globulin intravenous (human) | 607 | ||
| Usual dose (international units [IU]) | 607 | ||
| Dose adjustments (international units [IU]) | 607 | ||
| Dilution | 607 | ||
| Compatibility | 607 | ||
| Rate of administration | 608 | ||
| Actions | 608 | ||
| Indications and uses | 608 | ||
| Contraindications | 608 | ||
| Precautions | 608 | ||
| Drug/lab interactions | 609 | ||
| Side effects | 609 | ||
| Antidote | 609 | ||
| Hetastarch | 610 | ||
| Usual dose | 610 | ||
| Hespan, hextend | 610 | ||
| Shock: | 610 | ||
| I | 628 | ||
| Ibandronate sodium | 628 | ||
| Usual dose | 628 | ||
| Dose adjustments | 628 | ||
| Dilution | 629 | ||
| Compatibility | 629 | ||
| Rate of administration | 629 | ||
| Actions | 629 | ||
| Indications and uses | 629 | ||
| Contraindications | 629 | ||
| Precautions | 629 | ||
| Drug/lab interactions | 630 | ||
| Side effects | 630 | ||
| Antidote | 631 | ||
| Ibritumomab tiuxetan | 631 | ||
| Usual dose | 631 | ||
| Day 1 | 631 | ||
| K | 706 | ||
| Ketorolac tromethamine | 706 | ||
| Usual dose | 706 | ||
| Pediatric dose | 706 | ||
| Dose adjustments | 706 | ||
| Dilution | 706 | ||
| Compatibility | 706 | ||
| Rate of administration | 707 | ||
| Actions | 707 | ||
| Indications and uses | 707 | ||
| Contraindications | 707 | ||
| Precautions | 707 | ||
| Drug/lab interactions | 708 | ||
| Side effects | 708 | ||
| Antidote | 708 | ||
| L | 709 | ||
| Labetalol hydrochloride | 709 | ||
| Usual dose | 709 | ||
| Dose adjustments | 709 | ||
| Dilution | 709 | ||
| Compatibility (underline indicates conflicting compatibility information) | 709 | ||
| Rate of administration | 709 | ||
| Actions | 710 | ||
| Indications and uses | 710 | ||
| Contraindications | 710 | ||
| Precautions | 710 | ||
| Drug/lab interactions | 710 | ||
| Side effects | 711 | ||
| Antidote | 711 | ||
| Lacosamide | 712 | ||
| Usual dose | 712 | ||
| Dose adjustments | 712 | ||
| Dilution | 712 | ||
| Compatibility | 712 | ||
| Rate of administration | 712 | ||
| Actions | 712 | ||
| Indications and uses | 712 | ||
| Contraindications | 712 | ||
| Precautions | 713 | ||
| Drug/lab interactions | 714 | ||
| Side effects | 714 | ||
| Antidote | 714 | ||
| Lansoprazole | 715 | ||
| Usual dose | 715 | ||
| Dose adjustments | 715 | ||
| Dilution | 715 | ||
| Compatibility | 715 | ||
| Rate of administration | 715 | ||
| Actions | 715 | ||
| Indications and uses | 716 | ||
| Contraindications | 716 | ||
| Precautions | 716 | ||
| Drug/lab interactions | 716 | ||
| Side effects | 717 | ||
| Antidote | 717 | ||
| Leucovorin calcium | 718 | ||
| Usual dose | 718 | ||
| Dose adjustments | 718 | ||
| Dilution | 718 | ||
| Compatibility (underline indicates conflicting compatibility information) | 718 | ||
| Rate of administration | 719 | ||
| Actions | 719 | ||
| Indications and uses | 719 | ||
| Contraindications | 719 | ||
| Precautions | 719 | ||
| Drug/lab interactions | 720 | ||
| Side effects | 720 | ||
| Antidote | 720 | ||
| Levetiracetam injection | 721 | ||
| Usual dose | 721 | ||
| Dose adjustments | 721 | ||
| Dilution | 721 | ||
| Compatibility | 721 | ||
| Rate of administration | 722 | ||
| Actions | 722 | ||
| Indications and uses | 722 | ||
| Contraindications | 722 | ||
| Precautions | 722 | ||
| Drug/lab interactions | 723 | ||
| Side effects | 723 | ||
| Antidote | 723 | ||
| Levofloxacin | 724 | ||
| Usual dose | 724 | ||
| Dose adjustments | 724 | ||
| Dilution | 725 | ||
| Compatibility (underline indicates conflicting compatibility information) | 725 | ||
| Rate of administration | 726 | ||
| Actions | 726 | ||
| Indications and uses | 726 | ||
| Contraindications | 726 | ||
| Precautions | 726 | ||
| Drug/lab interactions | 728 | ||
| Side effects | 728 | ||
| Antidote | 729 | ||
| Levoleucovorin | 730 | ||
| Usual dose | 730 | ||
| Pediatric dose | 731 | ||
| Dose adjustments | 731 | ||
| Dilution | 731 | ||
| Compatibility | 731 | ||
| Rate of administration | 731 | ||
| Actions | 731 | ||
| Indications and uses | 732 | ||
| Contraindications | 732 | ||
| Precautions | 732 | ||
| Drug/lab interactions | 732 | ||
| Side effects | 733 | ||
| Antidote | 733 | ||
| Levothyroxine sodium | 734 | ||
| Usual dose | 734 | ||
| Pediatric dose | 734 | ||
| Dose adjustments | 734 | ||
| Dilution | 734 | ||
| Compatibility | 734 | ||
| Rate of administration | 734 | ||
| Actions | 734 | ||
| Indications and uses | 735 | ||
| Contraindications | 735 | ||
| Precautions | 735 | ||
| Drug/lab interactions | 735 | ||
| Side effects | 736 | ||
| Antidote | 736 | ||
| Lidocaine hydrochloride | 736 | ||
| Usual dose | 736 | ||
| Pediatric dose | 736 | ||
| Dose adjustments | 736 | ||
| Dilution | 737 | ||
| Compatibility (underline indicates conflicting compatibility information) | 737 | ||
| Rate of administration | 737 | ||
| Actions | 738 | ||
| Indications and uses | 738 | ||
| Contraindications | 738 | ||
| Precautions | 738 | ||
| Drug/lab interactions | 739 | ||
| Side effects | 739 | ||
| Antidote | 739 | ||
| Linezolid | 740 | ||
| Usual dose | 740 | ||
| Pediatric dose | 740 | ||
| Dose adjustments | 740 | ||
| Dilution | 740 | ||
| Compatibility (underline indicates conflicting compatibility information) | 741 | ||
| Rate of administration | 741 | ||
| Actions | 741 | ||
| Indications and uses | 742 | ||
| Contraindications | 742 | ||
| Precautions | 742 | ||
| Drug/lab interactions | 744 | ||
| Side effects | 744 | ||
| Antidote | 745 | ||
| Liothyronine sodium | 745 | ||
| Usual dose | 745 | ||
| Dose adjustments | 745 | ||
| Dilution | 745 | ||
| Compatibility | 745 | ||
| Rate of administration | 745 | ||
| Actions | 745 | ||
| Indications and uses | 746 | ||
| Contraindications | 746 | ||
| Precautions | 746 | ||
| Drug/lab interactions | 746 | ||
| Side effects | 747 | ||
| Antidote | 747 | ||
| Lorazepam | 748 | ||
| Usual dose | 748 | ||
| Pediatric dose | 748 | ||
| Dose adjustments | 748 | ||
| Dilution | 749 | ||
| Compatibility (underline indicates conflicting compatibility information) | 749 | ||
| Rate of administration | 750 | ||
| Actions | 750 | ||
| Indications and uses | 750 | ||
| Contraindications | 750 | ||
| Precautions | 750 | ||
| Drug/lab interactions | 751 | ||
| Side effects | 751 | ||
| Antidote | 751 | ||
| Lymphocyte immune globulin | 752 | ||
| Usual dose | 752 | ||
| Pediatric dose | 752 | ||
| Dilution | 752 | ||
| Compatibility | 752 | ||
| Rate of administration | 752 | ||
| Actions | 752 | ||
| Indications and uses | 752 | ||
| Contraindications | 752 | ||
| Precautions | 753 | ||
| Drug/lab interactions | 753 | ||
| Side effects | 753 | ||
| Antidote | 753 | ||
| M | 754 | ||
| Magnesium sulfate | 754 | ||
| Usual dose | 754 | ||
| Pediatric dose | 754 | ||
| Dose adjustments | 755 | ||
| Dilution | 755 | ||
| Compatibility (underline indicates conflicting compatibility information) | 755 | ||
| Rate of administration | 756 | ||
| Actions | 756 | ||
| Indications and uses | 756 | ||
| Contraindications | 756 | ||
| Precautions | 756 | ||
| Drug/lab interactions | 757 | ||
| Side effects | 757 | ||
| Antidote | 757 | ||
| Mannitol | 758 | ||
| Usual dose | 758 | ||
| Pediatric dose | 758 | ||
| Dose adjustments | 758 | ||
| Dilution | 759 | ||
| Compatibility (underline indicates conflicting compatibility information) | 759 | ||
| Rate of administration | 759 | ||
| Actions | 759 | ||
| Indications and uses | 760 | ||
| Contraindications | 760 | ||
| Precautions | 760 | ||
| Drug/lab interactions | 760 | ||
| Side effects | 760 | ||
| Antidote | 761 | ||
| Melphalan hydrochloride | 761 | ||
| Usual dose | 761 | ||
| Pediatric dose | 761 | ||
| Dose adjustments | 761 | ||
| Dilution | 761 | ||
| Compatibility (underline indicates conflicting compatibility information) | 762 | ||
| Rate of administration | 762 | ||
| Actions | 762 | ||
| Indications and uses | 762 | ||
| Contraindications | 763 | ||
| Precautions | 763 | ||
| Drug/lab interactions | 763 | ||
| Side effects | 763 | ||
| Antidote | 764 | ||
| Meperidine hydrochloride | 764 | ||
| Usual dose | 764 | ||
| Pediatric dose | 764 | ||
| Dose adjustments | 764 | ||
| Dilution | 764 | ||
| Compatibility (underline indicates conflicting compatibility information) | 765 | ||
| Rate of administration | 765 | ||
| Actions | 765 | ||
| Indications and uses | 765 | ||
| Contraindications | 765 | ||
| Precautions | 766 | ||
| Drug/lab interactions | 767 | ||
| Side effects | 767 | ||
| Antidote | 767 | ||
| Meropenem | 768 | ||
| Usual dose | 768 | ||
| Pediatric dose | 768 | ||
| Dose adjustments | 768 | ||
| Dilution | 769 | ||
| Compatibility (underline indicates conflicting compatibility information) | 769 | ||
| Rate of administration | 769 | ||
| Actions | 769 | ||
| Indications and uses | 770 | ||
| Contraindications | 770 | ||
| Precautions | 770 | ||
| Drug/lab interactions | 771 | ||
| Side effects | 771 | ||
| Antidote | 771 | ||
| Mesna | 772 | ||
| Usual dose | 772 | ||
| Dose adjustments | 772 | ||
| Dilution | 772 | ||
| Compatibility (underline indicates conflicting compatibility information) | 772 | ||
| Rate of administration | 772 | ||
| Actions | 773 | ||
| Indications and uses | 773 | ||
| Contraindications | 773 | ||
| Precautions | 773 | ||
| Drug/lab interactions | 773 | ||
| Side effects | 773 | ||
| Antidote | 773 | ||
| Methadone hydrochloride | 774 | ||
| Usual dose | 774 | ||
| Dose adjustments | 775 | ||
| Dilution | 775 | ||
| Compatibility (underline indicates conflicting compatibility information) | 775 | ||
| Rate of administration | 775 | ||
| Actions | 775 | ||
| Indications and uses | 775 | ||
| Contraindications | 776 | ||
| Precautions | 776 | ||
| Drug/lab interactions | 777 | ||
| Side effects | 778 | ||
| Antidote | 779 | ||
| Methotrexate sodium | 780 | ||
| Usual dose | 780 | ||
| Pediatric dose | 781 | ||
| Dose adjustments | 781 | ||
| Dilution | 781 | ||
| Compatibility (underline indicates conflicting compatibility information) | 781 | ||
| Rate of administration | 782 | ||
| Actions | 782 | ||
| Indications and uses | 782 | ||
| Contraindications | 782 | ||
| Precautions | 782 | ||
| Drug/lab interactions | 783 | ||
| Side effects | 784 | ||
| Antidote | 785 | ||
| Methylergonovine maleate | 786 | ||
| Usual dose | 786 | ||
| Dilution | 786 | ||
| Compatibility | 786 | ||
| Rate of administration | 786 | ||
| Actions | 786 | ||
| Indications and uses | 786 | ||
| Contraindications | 786 | ||
| Precautions | 786 | ||
| Drug/lab interactions | 787 | ||
| Side effects | 787 | ||
| Antidote | 787 | ||
| Methylprednisolone sodium succinate | 788 | ||
| Usual dose | 788 | ||
| Pediatric dose | 788 | ||
| Dose adjustments | 789 | ||
| Dilution | 789 | ||
| Compatibility (underline indicates conflicting compatibility information) | 789 | ||
| Rate of administration | 789 | ||
| Actions | 790 | ||
| Indications and uses | 790 | ||
| Contraindications | 790 | ||
| Precautions | 790 | ||
| Drug/lab interactions | 791 | ||
| Side effects | 792 | ||
| Antidote | 792 | ||
| Metoclopramide hydrochloride | 792 | ||
| Usual dose | 792 | ||
| Pediatric dose | 793 | ||
| Dose adjustments | 793 | ||
| Dilution | 793 | ||
| Compatibility (underline indicates conflicting compatibility information) | 793 | ||
| Rate of administration | 794 | ||
| Actions | 794 | ||
| Indications and uses | 794 | ||
| Contraindications | 794 | ||
| Precautions | 794 | ||
| Drug/lab interactions | 795 | ||
| Side effects | 795 | ||
| Antidote | 795 | ||
| Metoprolol tartrate | 796 | ||
| Usual dose | 796 | ||
| Dose adjustments | 796 | ||
| Dilution | 796 | ||
| Compatibility (underline indicates conflicting compatibility information) | 796 | ||
| Rate of administration | 796 | ||
| Actions | 796 | ||
| Indications and uses | 796 | ||
| Contraindications | 797 | ||
| Precautions | 797 | ||
| Drug/lab interactions | 797 | ||
| Side effects | 798 | ||
| Antidote | 798 | ||
| Metronidazole hydrochloride | 799 | ||
| Usual dose | 799 | ||
| Pediatric dose | 799 | ||
| Dose adjustments | 799 | ||
| Dilution | 799 | ||
| Compatibility (underline indicates conflicting compatibility information) | 800 | ||
| Rate of administration | 800 | ||
| Actions | 800 | ||
| Indications and uses | 800 | ||
| Contraindications | 800 | ||
| Precautions | 800 | ||
| Drug/lab interactions | 801 | ||
| Side effects | 801 | ||
| Antidote | 802 | ||
| Micafungin sodium | 802 | ||
| Usual dose | 802 | ||
| Dose adjustments | 802 | ||
| Dilution | 802 | ||
| Compatibility (underline indicates conflicting compatibility information) | 802 | ||
| Rate of administration | 803 | ||
| Actions | 803 | ||
| Indications and uses | 803 | ||
| Contraindications | 803 | ||
| Precautions | 803 | ||
| Drug/lab interactions | 804 | ||
| Side effects | 804 | ||
| Antidote | 805 | ||
| Midazolam hydrochloride | 805 | ||
| Usual dose | 805 | ||
| Sedation, anxiolysis (anti-anxiety), and/or amnesia for short diagnostic, endoscopic, and therapeutic procedures | 805 | ||
| Healthy adults less than 60 years of age: | 805 | ||
| Patients over 60 years of age or debilitated or chronically ill patients: | 805 | ||
| Induction of anesthesia before administration of other anesthetic agents and/or maintenance of anesthesia as a component o ... | 805 | ||
| Unpremedicated patients under 55 years of age: | 806 | ||
| Unpremedicated patients over 55 years of age (ASA I or II): | 806 | ||
| Unpremedicated debilitated patients or those with severe systemic disease (ASA III or IV): | 806 | ||
| Patients premedicated with sedatives or narcotics under 55 years of age: | 806 | ||
| Patients premedicated with sedatives or narcotics over 55 years of age (good risk [ASA I & II]): | 806 | ||
| Patients premedicated with sedatives or narcotics who are debilitated or those with severe systemic disease (ASA III or IV): | 806 | ||
| Sedation for anesthesia or treatment in a critical care setting for intubated and mechanically ventilated patients | 806 | ||
| Continuous infusion (concentration 0.5 mg/ml): | 806 | ||
| For maintenance of sedation: | 806 | ||
| Refractory status epilepticus (unlabeled) | 806 | ||
| Pediatric dose | 806 | ||
| Sedation, anxiolysis (antianxiety), and/or amnesia before and during procedures or before anesthesia | 806 | ||
| Nonintubated infants less than 6 months of age: | 806 | ||
| Pediatric patients 6 months to 5 years of age: | 807 | ||
| Pediatric patients 6 to 12 years of age: | 807 | ||
| Pediatric patients 12 to 16 years of age: | 807 | ||
| Sedation, anxiolysis, amnesia | 807 | ||
| Intubated pediatric patients in critical care settings: | 807 | ||
| Sedation of intubated neonates in critical care settings | 807 | ||
| Neonates less than 32 weeks: | 807 | ||
| Neonates 32 weeks or older: | 807 | ||
| Refractory status epilepticus (unlabeled) | 807 | ||
| Pediatric patients 2 months of age or older: | 807 | ||
| Loading dose: | 807 | ||
| Dose adjustments | 807 | ||
| Dilution | 807 | ||
| Compatibility (underline indicates conflicting compatibility information) | 807 | ||
| Rate of administration | 808 | ||
| Actions | 808 | ||
| Indications and uses | 808 | ||
| Contraindications | 808 | ||
| Precautions | 809 | ||
| Drug/lab interactions | 809 | ||
| Side effects | 810 | ||
| Antidote | 810 | ||
| Milrinone lactate | 811 | ||
| Usual dose | 811 | ||
| Dose adjustments | 811 | ||
| Dilution | 811 | ||
| Compatibility (underline indicates conflicting compatibility information) | 812 | ||
| Rate of administration | 812 | ||
| Actions | 813 | ||
| Indications and uses | 813 | ||
| Contraindications | 813 | ||
| Precautions | 813 | ||
| Drug/lab interactions | 814 | ||
| Side effects | 814 | ||
| Antidote | 814 | ||
| Mitomycin | 815 | ||
| Usual dose | 815 | ||
| Dose adjustments | 815 | ||
| Dilution | 815 | ||
| Compatibility (underline indicates conflicting compatibility information) | 815 | ||
| Rate of administration | 815 | ||
| Actions | 816 | ||
| Indications and uses | 816 | ||
| Contraindications | 816 | ||
| Precautions | 816 | ||
| Drug/lab interactions | 817 | ||
| Side effects | 817 | ||
| Antidote | 817 | ||
| Mitoxantrone hydrochloride | 818 | ||
| Usual dose | 818 | ||
| Dose adjustments | 818 | ||
| Dilution | 818 | ||
| Compatibility | 818 | ||
| Rate of administration | 819 | ||
| Actions | 819 | ||
| Indications and uses | 819 | ||
| Contraindications | 819 | ||
| Precautions | 819 | ||
| Drug/lab interactions | 820 | ||
| Side effects | 820 | ||
| Antidote | 821 | ||
| Morphine sulfate | 822 | ||
| Usual dose | 822 | ||
| Pediatric dose | 822 | ||
| Neonatal dose | 822 | ||
| Dose adjustments | 823 | ||
| Dilution | 823 | ||
| Compatibility (underline indicates conflicting compatibility information) | 823 | ||
| Rate of administration | 824 | ||
| Actions | 824 | ||
| Indications and uses | 824 | ||
| Contraindications | 824 | ||
| Precautions | 824 | ||
| Drug/lab interactions | 825 | ||
| Side effects | 826 | ||
| Antidote | 826 | ||
| Moxifloxacin hydrochloride | 826 | ||
| Usual dose | 826 | ||
| Dose adjustments | 827 | ||
| Dilution | 827 | ||
| Compatibility | 827 | ||
| Rate of administration | 827 | ||
| Actions | 827 | ||
| Indications and uses | 827 | ||
| Contraindications | 828 | ||
| Precautions | 828 | ||
| Drug/lab interactions | 829 | ||
| Side effects | 829 | ||
| Antidote | 830 | ||
| Multivitamin infusion | 831 | ||
| Usual dose | 831 | ||
| Pediatric dose | 831 | ||
| Infuvite pediatric | 831 | ||
| N | 841 | ||
| Nafcillin sodium | 841 | ||
| Usual dose | 841 | ||
| Pediatric dose | 841 | ||
| Neonatal dose | 841 | ||
| Dose adjustments | 841 | ||
| Dilution | 841 | ||
| Compatibility (underline indicates conflicting compatibility information) | 842 | ||
| Rate of administration | 842 | ||
| Actions | 842 | ||
| Indications and uses | 842 | ||
| Contraindications | 842 | ||
| Precautions | 842 | ||
| Drug/lab interactions | 843 | ||
| Side effects | 843 | ||
| Antidote | 843 | ||
| Nalbuphine hydrochloride | 844 | ||
| Usual dose | 844 | ||
| Dose adjustments | 844 | ||
| Dilution | 844 | ||
| Compatibility | 844 | ||
| Rate of administration | 844 | ||
| Actions | 844 | ||
| Indications and uses | 844 | ||
| Contraindications | 845 | ||
| Precautions | 845 | ||
| Drug/lab interactions | 845 | ||
| Side effects | 846 | ||
| Antidote | 846 | ||
| Naloxone hydrochloride | 846 | ||
| Usual dose | 846 | ||
| Pediatric dose | 846 | ||
| Neonatal dose | 846 | ||
| Dilution | 847 | ||
| Compatibility | 847 | ||
| Rate of administration | 847 | ||
| Actions | 847 | ||
| Indications and uses | 847 | ||
| Contraindications | 847 | ||
| Precautions | 847 | ||
| Drug/lab interactions | 847 | ||
| Side effects | 847 | ||
| Antidote | 847 | ||
| Natalizumab | 848 | ||
| Usual dose | 848 | ||
| Dose adjustments | 848 | ||
| Dilution | 848 | ||
| Compatibility | 848 | ||
| Rate of administration | 848 | ||
| Actions | 848 | ||
| Indications and uses | 849 | ||
| Contraindications | 849 | ||
| Precautions | 849 | ||
| Drug/lab interactions | 850 | ||
| Side effects | 851 | ||
| Antidote | 851 | ||
| Nelarabine | 852 | ||
| Usual dose | 852 | ||
| Pediatric dose | 852 | ||
| Dose adjustments | 852 | ||
| Dilution | 852 | ||
| Compatibility | 852 | ||
| Rate of administration | 852 | ||
| Actions | 852 | ||
| Indications and uses | 852 | ||
| Contraindications | 852 | ||
| Precautions | 853 | ||
| Drug/lab interactions | 853 | ||
| Side effects | 853 | ||
| Antidote | 854 | ||
| Neostigmine methylsulfate | 855 | ||
| Usual dose | 855 | ||
| Pediatric dose | 855 | ||
| Dose adjustments | 855 | ||
| Dilution | 855 | ||
| Compatibility (underline indicates conflicting compatibility information) | 855 | ||
| Rate of administration | 855 | ||
| Actions | 855 | ||
| Indications and uses | 855 | ||
| Contraindications | 856 | ||
| Precautions | 856 | ||
| Drug/lab interactions | 856 | ||
| Side effects | 856 | ||
| Antidote | 856 | ||
| Nesiritide | 857 | ||
| Usual dose | 857 | ||
| Dose adjustments | 857 | ||
| Dilution | 857 | ||
| Compatibility (underline indicates conflicting compatibility information) | 857 | ||
| Rate of administration | 858 | ||
| Actions | 858 | ||
| Indications and uses | 858 | ||
| Contraindications | 859 | ||
| Precautions | 859 | ||
| Drug/lab interactions | 859 | ||
| Side effects | 859 | ||
| Antidote | 860 | ||
| Nicardipine hydrochloride | 861 | ||
| Usual dose | 861 | ||
| Dose adjustments | 861 | ||
| Dilution | 861 | ||
| Compatibility (underline indicates conflicting compatibility information) | 861 | ||
| Rate of administration | 862 | ||
| Actions | 862 | ||
| Indications and uses | 862 | ||
| Contraindications | 862 | ||
| Precautions | 862 | ||
| Drug/lab interactions | 863 | ||
| Side effects | 863 | ||
| Antidote | 863 | ||
| Nitroglycerin IV | 864 | ||
| Usual dose | 864 | ||
| Pediatric dose | 864 | ||
| Dose adjustments | 864 | ||
| Dilution | 864 | ||
| Compatibility (underline indicates conflicting compatibility information) | 865 | ||
| Rate of administration | 865 | ||
| Actions | 866 | ||
| Indications and uses | 866 | ||
| Contraindications | 866 | ||
| Precautions | 866 | ||
| Drug/lab interactions | 867 | ||
| Side effects | 867 | ||
| Antidote | 867 | ||
| Nitroprusside sodium | 868 | ||
| Usual dose | 868 | ||
| Pediatric dose | 868 | ||
| Dose adjustments | 868 | ||
| Dilution | 868 | ||
| Compatibility (underline indicates conflicting compatibility information) | 868 | ||
| Rate of administration | 869 | ||
| Actions | 869 | ||
| Indications and uses | 869 | ||
| Contraindications | 869 | ||
| Precautions | 869 | ||
| Drug/lab interactions | 870 | ||
| Side effects | 870 | ||
| Antidote | 870 | ||
| Norepinephrine bitartrate | 871 | ||
| Usual dose | 871 | ||
| Pediatric dose | 871 | ||
| Dose adjustments | 871 | ||
| Dilution | 871 | ||
| Compatibility (underline indicates conflicting compatibility information) | 871 | ||
| Rate of administration | 872 | ||
| Actions | 872 | ||
| Indications and uses | 872 | ||
| Contraindications | 872 | ||
| Precautions | 872 | ||
| Drug/lab interactions | 873 | ||
| Side effects | 873 | ||
| Antidote | 873 | ||
| O | 874 | ||
| Octreotide acetate | 874 | ||
| Usual dose | 874 | ||
| Pediatric dose | 874 | ||
| Dose adjustments | 874 | ||
| Dilution | 875 | ||
| Compatibility (underline indicates conflicting compatibility information) | 875 | ||
| Rate of administration | 875 | ||
| Actions | 875 | ||
| Indications and uses | 875 | ||
| Contraindications | 875 | ||
| Precautions | 875 | ||
| Drug/lab interactions | 876 | ||
| Side effects | 877 | ||
| Antidote | 877 | ||
| Ofatumumab | 878 | ||
| Usual dose | 878 | ||
| Dose adjustments | 878 | ||
| Dilution | 878 | ||
| Compatibility | 878 | ||
| Rate of administration | 878 | ||
| Actions | 879 | ||
| Indications and uses | 879 | ||
| Contraindications | 879 | ||
| Precautions | 879 | ||
| Drug/lab interactions | 880 | ||
| Side effects | 880 | ||
| Antidote | 880 | ||
| Ondansetron hydrochloride | 881 | ||
| Usual dose | 881 | ||
| Pediatric dose | 881 | ||
| Dose adjustments | 881 | ||
| Dilution | 881 | ||
| Compatibility (underline indicates conflicting compatibility information) | 881 | ||
| Rate of administration | 882 | ||
| Actions | 882 | ||
| Indications and uses | 882 | ||
| Contraindications | 882 | ||
| Precautions | 882 | ||
| Drug/lab interactions | 883 | ||
| Side effects | 883 | ||
| Antidote | 884 | ||
| Oxacillin sodium | 884 | ||
| Usual dose | 884 | ||
| Pediatric dose | 884 | ||
| Neonatal dose | 884 | ||
| Dose adjustments | 884 | ||
| Dilution | 884 | ||
| Compatibility (underline indicates conflicting compatibility information) | 885 | ||
| Rate of administration | 885 | ||
| Actions | 885 | ||
| Indications and uses | 885 | ||
| Contraindications | 885 | ||
| Precautions | 885 | ||
| Drug/lab interactions | 886 | ||
| Side effects | 886 | ||
| Antidote | 886 | ||
| Oxaliplatin | 887 | ||
| Usual dose | 887 | ||
| Dose adjustments | 887 | ||
| Dilution | 887 | ||
| Compatibility (underline indicates conflicting compatibility information) | 888 | ||
| Rate of administration | 888 | ||
| Actions | 888 | ||
| Indications and uses | 888 | ||
| Contraindications | 889 | ||
| Precautions | 889 | ||
| Drug/lab interactions | 890 | ||
| Side effects | 890 | ||
| Antidote | 891 | ||
| Oxymorphone hydrochloride | 891 | ||
| Usual dose | 891 | ||
| Dose adjustments | 891 | ||
| Dilution | 891 | ||
| Compatibility | 891 | ||
| Rate of administration | 891 | ||
| Actions | 891 | ||
| Indications and uses | 892 | ||
| Contraindications | 892 | ||
| Precautions | 892 | ||
| Drug/lab interactions | 893 | ||
| Side effects | 893 | ||
| Antidote | 893 | ||
| Oxytocin injection | 894 | ||
| Usual dose | 894 | ||
| Dilution | 894 | ||
| Compatibility | 894 | ||
| Rate of administration | 894 | ||
| Actions | 895 | ||
| Indications and uses | 895 | ||
| Contraindications | 895 | ||
| Precautions | 895 | ||
| Drug/lab interactions | 896 | ||
| Side effects | 896 | ||
| Antidote | 896 | ||
| P | 897 | ||
| Paclitaxel • paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 897 | ||
| Usual dose | 897 | ||
| Conventional paclitaxel | 897 | ||
| Ovarian cancer in previously untreated patients: | 897 | ||
| Ovarian cancer in patients previously treated with chemotherapy: | 897 | ||
| Adjuvant treatment of node-positive breast cancer: | 897 | ||
| Breast cancer in patients previously treated with chemotherapy: | 897 | ||
| First-line treatment of non–small-cell lung cancer: | 897 | ||
| AIDS-related kaposi’s sarcoma: | 897 | ||
| Abraxane | 897 | ||
| Premedication: | 897 | ||
| Metastatic breast cancer (MBC): | 897 | ||
| Non–small cell lung cancer (NSCLC): | 897 | ||
| Dose adjustments | 898 | ||
| Conventional paclitaxel | 898 | ||
| Abraxane | 898 | ||
| Dilution | 899 | ||
| Conventional paclitaxel | 899 | ||
| Abraxane | 900 | ||
| Filters: | 900 | ||
| Q | 1032 | ||
| Quinidine gluconate injection | 1032 | ||
| Usual dose | 1032 | ||
| Pediatric dose | 1032 | ||
| Dose adjustments | 1032 | ||
| Dilution | 1032 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1033 | ||
| Rate of administration | 1033 | ||
| Actions | 1033 | ||
| Indications and uses | 1033 | ||
| Contraindications | 1033 | ||
| Precautions | 1033 | ||
| Drug/lab interactions | 1034 | ||
| Side effects | 1035 | ||
| Antidote | 1035 | ||
| Quinupristin/dalfopristin | 1036 | ||
| Usual dose | 1036 | ||
| Pediatric dose | 1036 | ||
| Dose adjustments | 1036 | ||
| Dilution | 1036 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1036 | ||
| Rate of administration | 1036 | ||
| Actions | 1036 | ||
| Indications and uses | 1037 | ||
| Contraindications | 1037 | ||
| Precautions | 1037 | ||
| Drug/lab interactions | 1037 | ||
| Side effects | 1038 | ||
| Antidote | 1038 | ||
| R | 1039 | ||
| Ranitidine | 1039 | ||
| Usual dose | 1039 | ||
| Pediatric dose | 1039 | ||
| Neonatal dose | 1039 | ||
| Dose adjustments | 1039 | ||
| Dilution | 1039 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1040 | ||
| Rate of administration | 1040 | ||
| Actions | 1041 | ||
| Indications and uses | 1041 | ||
| Contraindications | 1041 | ||
| Precautions | 1041 | ||
| Drug/lab interactions | 1041 | ||
| Side effects | 1042 | ||
| Antidote | 1042 | ||
| Rasburicase | 1042 | ||
| Usual dose | 1042 | ||
| Pediatric dose | 1042 | ||
| Dose adjustments | 1042 | ||
| Dilution | 1042 | ||
| Compatibility | 1043 | ||
| Rate of administration | 1043 | ||
| Actions | 1043 | ||
| Indications and uses | 1043 | ||
| Contraindications | 1043 | ||
| Precautions | 1043 | ||
| Drug/lab interactions | 1044 | ||
| Side effects | 1044 | ||
| Antidote | 1044 | ||
| Raxibacumab | 1044 | ||
| Usual dose | 1044 | ||
| Pediatric dose | 1044 | ||
| Dose adjustments | 1044 | ||
| Dilution | 1044 | ||
| Compatibility | 1045 | ||
| Rate of administration | 1045 | ||
| Actions | 1045 | ||
| Indications and uses | 1046 | ||
| Contraindications | 1046 | ||
| Precautions | 1046 | ||
| Monitor | 1046 | ||
| Drug/lab interactions | 1046 | ||
| Side effects | 1046 | ||
| Antidote | 1046 | ||
| Regadenoson | 1047 | ||
| Usual dose | 1047 | ||
| Dose adjustments | 1047 | ||
| Dilution | 1047 | ||
| Compatibility | 1047 | ||
| Rate of administration | 1047 | ||
| Actions | 1047 | ||
| Indications and uses | 1047 | ||
| Contraindications | 1047 | ||
| Precautions | 1047 | ||
| Drug/lab interactions | 1048 | ||
| Side effects | 1048 | ||
| Antidote | 1049 | ||
| Reteplase recombinant | 1049 | ||
| Usual dose | 1049 | ||
| Dose adjustments | 1049 | ||
| Dilution | 1049 | ||
| Compatibility | 1049 | ||
| Rate of administration | 1049 | ||
| Actions | 1050 | ||
| Indications and uses | 1050 | ||
| Contraindications | 1050 | ||
| Precautions | 1050 | ||
| Drug/lab interactions | 1051 | ||
| Side effects | 1051 | ||
| Antidote | 1051 | ||
| Rho(D) immune globulin intravenous (human) | 1052 | ||
| Usual dose(international units [IU]) | 1052 | ||
| Pediatric dose | 1053 | ||
| Dose adjustments (international units [IU]) | 1053 | ||
| Dilution (international units [IU]) | 1053 | ||
| Compatibility | 1054 | ||
| Rate of administration | 1054 | ||
| Actions (international units [IU]) | 1054 | ||
| Indications and uses | 1054 | ||
| Contraindications | 1054 | ||
| Precautions | 1055 | ||
| Drug/lab interactions | 1056 | ||
| Side effects | 1056 | ||
| Antidote | 1056 | ||
| Rifampin | 1057 | ||
| Usual dose | 1057 | ||
| Pediatric dose | 1057 | ||
| Dose adjustments | 1057 | ||
| Dilution | 1057 | ||
| Compatibility | 1057 | ||
| Rate of administration | 1057 | ||
| Actions | 1057 | ||
| Indications and uses | 1058 | ||
| Contraindications | 1058 | ||
| Precautions | 1058 | ||
| Drug/lab interactions | 1059 | ||
| Side effects | 1060 | ||
| Antidote | 1060 | ||
| Rituximab | 1060 | ||
| Usual dose | 1060 | ||
| Dose adjustments | 1061 | ||
| Dilution | 1061 | ||
| Compatibility | 1061 | ||
| Rate of administration | 1062 | ||
| Actions | 1062 | ||
| Indications and uses | 1063 | ||
| Contraindications | 1063 | ||
| Precautions | 1063 | ||
| Drug/lab interactions | 1065 | ||
| Side effects | 1066 | ||
| Antidote | 1067 | ||
| Romidepsin | 1068 | ||
| Usual dose | 1068 | ||
| Dose adjustments | 1068 | ||
| Dilution | 1068 | ||
| Compatibility | 1068 | ||
| Rate of administration | 1069 | ||
| Actions | 1069 | ||
| Indications and uses | 1069 | ||
| Contraindications | 1069 | ||
| Precautions | 1069 | ||
| Drug/lab interactions | 1070 | ||
| Side effects | 1070 | ||
| Antidote | 1070 | ||
| S | 1071 | ||
| Sargramostim | 1071 | ||
| Usual dose | 1071 | ||
| Dose adjustments | 1071 | ||
| Dilution | 1071 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1072 | ||
| Rate of administration | 1072 | ||
| Actions | 1072 | ||
| Indications and uses | 1073 | ||
| Contraindications | 1073 | ||
| Precautions | 1073 | ||
| Drug/lab interactions | 1073 | ||
| Side effects | 1073 | ||
| Antidote | 1074 | ||
| Sildenafil * | 1074 | ||
| Usual dose | 1074 | ||
| Dose adjustments | 1074 | ||
| Dilution | 1074 | ||
| Compatibility | 1074 | ||
| Rate of administration | 1074 | ||
| Actions | 1074 | ||
| Indications and uses | 1074 | ||
| Contraindications | 1075 | ||
| Precautions | 1075 | ||
| Drug/lab interactions | 1076 | ||
| Side effects | 1076 | ||
| Antidote | 1076 | ||
| Sipuleucel-T | 1077 | ||
| Usual dose | 1077 | ||
| Dilution | 1077 | ||
| Compatibility | 1077 | ||
| Rate of administration | 1077 | ||
| Actions | 1077 | ||
| Indications and uses | 1078 | ||
| Contraindications | 1078 | ||
| Precautions | 1078 | ||
| Drug/lab interactions | 1078 | ||
| Side effects | 1078 | ||
| Antidote | 1079 | ||
| Sodium acetate | 1079 | ||
| Usual dose | 1079 | ||
| Dose adjustments | 1079 | ||
| Dilution | 1079 | ||
| Compatibility | 1079 | ||
| Rate of administration | 1079 | ||
| Actions | 1079 | ||
| Indications and uses | 1079 | ||
| Contraindications | 1080 | ||
| Precautions | 1080 | ||
| Drug/lab interactions | 1080 | ||
| Side effects | 1080 | ||
| Antidote | 1080 | ||
| Sodium bicarbonate | 1081 | ||
| Usual dose | 1081 | ||
| Pediatric dose | 1081 | ||
| Dilution | 1081 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1081 | ||
| Rate of administration | 1082 | ||
| Actions | 1082 | ||
| Indications and uses | 1082 | ||
| Contraindications | 1082 | ||
| Precautions | 1082 | ||
| Drug/lab interactions | 1083 | ||
| Side effects | 1083 | ||
| Antidote | 1083 | ||
| Sodium chloride | 1084 | ||
| Usual dose | 1084 | ||
| Dose adjustments | 1084 | ||
| Dilution | 1084 | ||
| Compatibility | 1085 | ||
| Rate of administration | 1085 | ||
| Actions | 1085 | ||
| Indications and uses | 1085 | ||
| Contraindications | 1085 | ||
| Precautions | 1085 | ||
| Drug/lab interactions | 1086 | ||
| Side effects | 1086 | ||
| Antidote | 1086 | ||
| Sodium ferric gluconate complex | 1087 | ||
| Usual dose | 1087 | ||
| Pediatric dose | 1087 | ||
| Dose adjustments | 1087 | ||
| Dilution | 1087 | ||
| Compatibility | 1087 | ||
| Rate of administration | 1087 | ||
| Actions | 1087 | ||
| Indications and uses | 1087 | ||
| Contraindications | 1088 | ||
| Precautions | 1088 | ||
| Drug/lab interactions | 1088 | ||
| Side effects | 1088 | ||
| Antidote | 1089 | ||
| Sodium phenylacetate and sodium benzoate | 1090 | ||
| Usual dose | 1090 | ||
| Dose adjustments | 1091 | ||
| Dilution | 1091 | ||
| Compatibility | 1091 | ||
| Rate of administration | 1091 | ||
| Actions | 1092 | ||
| Indications and uses | 1092 | ||
| Contraindications | 1092 | ||
| Precautions | 1092 | ||
| Drug/lab interactions | 1093 | ||
| Side effects | 1094 | ||
| Antidote | 1094 | ||
| Sotalol hydrochloride | 1095 | ||
| Usual dose | 1095 | ||
| Dose adjustments | 1095 | ||
| Dilution | 1095 | ||
| Compatibility | 1096 | ||
| Rate of administration | 1096 | ||
| Actions | 1096 | ||
| Indications and uses | 1096 | ||
| Contraindications | 1096 | ||
| Precautions | 1096 | ||
| Drug/lab interactions | 1097 | ||
| Side effects | 1098 | ||
| Antidote | 1098 | ||
| Streptomycin sulfate | 1099 | ||
| Usual dose | 1099 | ||
| All IV doses and uses are unlabeled. | 1099 | ||
| Mycobacterium tuberculosis (unlabeled): | 1099 | ||
| Mycobacterium avium complex (unlabeled): | 1099 | ||
| Dose adjustments | 1099 | ||
| Dilution | 1099 | ||
| Compatibility | 1099 | ||
| Rate of administration | 1099 | ||
| Actions | 1099 | ||
| Indications and uses | 1099 | ||
| Contraindications | 1100 | ||
| Precautions | 1100 | ||
| Drug/lab interactions | 1101 | ||
| Side effects | 1101 | ||
| Antidote | 1101 | ||
| Streptozocin | 1102 | ||
| Usual dose | 1102 | ||
| Dose adjustments | 1102 | ||
| Dilution | 1102 | ||
| Compatibility | 1102 | ||
| Rate of administration | 1102 | ||
| Actions | 1102 | ||
| Indications and uses | 1102 | ||
| Contraindications | 1102 | ||
| Precautions | 1102 | ||
| Drug/lab interactions | 1103 | ||
| Side effects | 1103 | ||
| Antidote | 1103 | ||
| Sulfamethoxazole and trimethoprim | 1104 | ||
| Usual dose | 1104 | ||
| Dose adjustments | 1104 | ||
| Dilution | 1104 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1104 | ||
| Rate of administration | 1104 | ||
| Actions | 1105 | ||
| Indications and uses | 1105 | ||
| Contraindications | 1105 | ||
| Precautions | 1105 | ||
| Drug/lab interactions | 1105 | ||
| Side effects | 1106 | ||
| Antidote | 1106 | ||
| T | 1107 | ||
| Tacrolimus | 1107 | ||
| Usual dose | 1107 | ||
| Pediatric dose | 1107 | ||
| Dose adjustments | 1107 | ||
| Dilution | 1107 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1108 | ||
| Rate of administration | 1108 | ||
| Actions | 1108 | ||
| Indications and uses | 1108 | ||
| Contraindications | 1109 | ||
| Precautions | 1109 | ||
| Drug/lab interactions | 1110 | ||
| Side effects | 1111 | ||
| Antidote | 1112 | ||
| Taliglucerase alfa | 1112 | ||
| Usual dose | 1112 | ||
| Dose adjustments | 1112 | ||
| Dilution | 1112 | ||
| Compatibility | 1113 | ||
| Rate of administration | 1113 | ||
| Actions | 1113 | ||
| Indications and uses | 1113 | ||
| Contraindications | 1113 | ||
| Precautions | 1113 | ||
| Drug/lab interactions | 1113 | ||
| Side effects | 1114 | ||
| Antidote | 1114 | ||
| Telavancin | 1115 | ||
| Usual dose | 1115 | ||
| Dose adjustments | 1115 | ||
| Dilution | 1115 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1115 | ||
| Rate of administration | 1116 | ||
| Actions | 1116 | ||
| Indications and uses | 1116 | ||
| Contraindications | 1116 | ||
| Precautions | 1116 | ||
| Drug/lab interactions | 1117 | ||
| Side effects | 1117 | ||
| Antidote | 1117 | ||
| Temozolomide | 1118 | ||
| Usual dose | 1118 | ||
| Dose adjustments | 1119 | ||
| Dilution | 1120 | ||
| Compatibility | 1120 | ||
| Rate of administration | 1120 | ||
| Actions | 1120 | ||
| Indications and uses | 1121 | ||
| Contraindications | 1121 | ||
| Precautions | 1121 | ||
| Drug/lab interactions | 1122 | ||
| Side effects | 1122 | ||
| Antidote | 1122 | ||
| Temsirolimus | 1123 | ||
| Usual dose | 1123 | ||
| Dose adjustments | 1123 | ||
| Dilution | 1123 | ||
| Compatibility | 1123 | ||
| Rate of administration | 1124 | ||
| Actions | 1124 | ||
| Indications and uses | 1124 | ||
| Contraindications | 1124 | ||
| Precautions | 1124 | ||
| Drug/lab interactions | 1125 | ||
| Side effects | 1126 | ||
| Antidote | 1126 | ||
| Tenecteplase | 1127 | ||
| Usual dose | 1127 | ||
| Dose adjustments | 1127 | ||
| Dilution | 1127 | ||
| Compatibility | 1128 | ||
| Rate of administration | 1128 | ||
| Actions | 1128 | ||
| Indications and uses | 1128 | ||
| Contraindications | 1128 | ||
| Precautions | 1128 | ||
| Drug/lab interactions | 1129 | ||
| Side effects | 1129 | ||
| Antidote | 1129 | ||
| Teniposide | 1130 | ||
| Usual dose | 1130 | ||
| Pediatric dose | 1130 | ||
| Dose adjustments | 1130 | ||
| Dilution | 1130 | ||
| Compatibility | 1131 | ||
| Rate of administration | 1131 | ||
| Actions | 1131 | ||
| Indications and uses | 1131 | ||
| Contraindications | 1132 | ||
| Precautions | 1132 | ||
| Drug/lab interactions | 1133 | ||
| Side effects | 1133 | ||
| Antidote | 1133 | ||
| Thiamine hydrochloride | 1134 | ||
| Usual dose | 1134 | ||
| Pediatric dose | 1134 | ||
| Dilution | 1134 | ||
| Compatibility | 1134 | ||
| Rate of administration | 1134 | ||
| Actions | 1134 | ||
| Indications and uses | 1134 | ||
| Contraindications | 1135 | ||
| Precautions | 1135 | ||
| Side effects | 1135 | ||
| Antidote | 1135 | ||
| Thiotepa | 1136 | ||
| Usual dose | 1136 | ||
| Dose adjustments | 1136 | ||
| Dilution | 1136 | ||
| Compatibility | 1136 | ||
| Rate of administration | 1137 | ||
| Actions | 1137 | ||
| Indications and uses | 1137 | ||
| Contraindications | 1137 | ||
| Precautions | 1137 | ||
| Drug/lab interactions | 1137 | ||
| Side effects | 1137 | ||
| Antidote | 1138 | ||
| Ticarcillin disodium and clavulanate potassium | 1138 | ||
| Usual dose | 1138 | ||
| Pediatric dose | 1138 | ||
| Neonatal dose | 1138 | ||
| Dose adjustments | 1139 | ||
| Dilution | 1139 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1139 | ||
| Rate of administration | 1140 | ||
| Actions | 1140 | ||
| Indications and uses | 1140 | ||
| Contraindications | 1140 | ||
| Precautions | 1140 | ||
| Drug/lab interactions | 1141 | ||
| Side effects | 1141 | ||
| Antidote | 1141 | ||
| Tigecycline for injection | 1142 | ||
| Usual dose | 1142 | ||
| Dose adjustments | 1142 | ||
| Dilution | 1142 | ||
| Compatibility | 1142 | ||
| Rate of administration | 1143 | ||
| Actions | 1143 | ||
| Indications and uses | 1143 | ||
| Contraindications | 1143 | ||
| Precautions | 1143 | ||
| Drug/lab interactions | 1144 | ||
| Side effects | 1144 | ||
| Antidote | 1144 | ||
| Tirofiban hydrochloride | 1145 | ||
| Usual dose | 1145 | ||
| Dose adjustments | 1145 | ||
| Dilution | 1145 | ||
| Compatibility | 1145 | ||
| Rate of administration | 1145 | ||
| Actions | 1146 | ||
| Indications and uses | 1146 | ||
| Contraindications | 1146 | ||
| Precautions | 1147 | ||
| Drug/lab interactions | 1148 | ||
| Side effects | 1149 | ||
| Antidote | 1149 | ||
| Tobramycin sulfate | 1150 | ||
| Usual dose | 1150 | ||
| Pediatric dose | 1150 | ||
| Neonatal dose | 1150 | ||
| Dose adjustments | 1150 | ||
| Dilution | 1150 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1151 | ||
| Rate of administration | 1151 | ||
| Actions | 1151 | ||
| Indications and uses | 1151 | ||
| Contraindications | 1151 | ||
| Precautions | 1151 | ||
| Drug/lab interactions | 1152 | ||
| Side effects | 1153 | ||
| Antidote | 1153 | ||
| Tocilizumab | 1154 | ||
| Usual dose | 1154 | ||
| Dose adjustments | 1154 | ||
| Dilution | 1155 | ||
| Compatibility | 1155 | ||
| Rate of administration | 1155 | ||
| Actions | 1155 | ||
| Indications and uses | 1155 | ||
| Contraindications | 1156 | ||
| Precautions | 1156 | ||
| Drug/lab interactions | 1157 | ||
| Side effects | 1157 | ||
| Antidote | 1158 | ||
| Topotecan hydrochloride | 1158 | ||
| Usual dose | 1158 | ||
| Dose adjustments | 1158 | ||
| Dilution | 1159 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1159 | ||
| Rate of administration | 1159 | ||
| Actions | 1159 | ||
| Indications and uses | 1159 | ||
| Contraindications | 1159 | ||
| Precautions | 1159 | ||
| Drug/lab interactions | 1160 | ||
| Side effects | 1161 | ||
| Antidote | 1161 | ||
| Torsemide injection | 1162 | ||
| Usual dose | 1162 | ||
| Dose adjustments | 1162 | ||
| Dilution | 1162 | ||
| Compatibility | 1162 | ||
| Rate of administration | 1162 | ||
| Actions | 1162 | ||
| Indications and uses | 1163 | ||
| Contraindications | 1163 | ||
| Precautions | 1163 | ||
| Drug/lab interactions | 1164 | ||
| Side effects | 1165 | ||
| Antidote | 1165 | ||
| Tositumomab and iodine-131 tositumomab | 1166 | ||
| Usual dose | 1166 | ||
| Pretesting | 1166 | ||
| Premedication | 1166 | ||
| Prophylaxis to reduce the risk of hypothyroidism: | 1166 | ||
| Prophylaxis to prevent or reduce infusion reactions: | 1166 | ||
| Acetaminophen: | 1166 | ||
| Diphenhydramine: | 1166 | ||
| Day before dosimetric step (day −1) | 1166 | ||
| Day of dosimetric step (day 0) | 1166 | ||
| Tositumomab: | 1166 | ||
| Biodistribution: | 1166 | ||
| 1st image (scan): | 1166 | ||
| 2nd image (scan): | 1166 | ||
| 3rd image (scan): | 1166 | ||
| Day 6 or 7 | 1166 | ||
| Assessment of biodistribution of I-131 tositumomab: | 1166 | ||
| If biodistribution is not acceptable, stop therapy now. | 1166 | ||
| Therapeutic step: Day 7 to day 14 (select one day) | 1167 | ||
| Thyroid-protective agents: | 1167 | ||
| Tositumomab: | 1167 | ||
| Platelets equal to or greater than 150,000/mm3: | 1167 | ||
| Platelets 100,000/mm3 to 149,000/mm3: | 1167 | ||
| Dose adjustments | 1167 | ||
| Dilution | 1167 | ||
| Compatibility | 1168 | ||
| Rate of administration | 1168 | ||
| Actions | 1168 | ||
| Indications and uses | 1169 | ||
| Contraindications | 1169 | ||
| Precautions | 1169 | ||
| Drug/lab interactions | 1170 | ||
| Side effects | 1170 | ||
| Antidote | 1171 | ||
| Trace metals | 1172 | ||
| Usual dose | 1172 | ||
| Pediatric dose | 1172 | ||
| Dose adjustments | 1172 | ||
| Dilution | 1172 | ||
| Compatibility | 1172 | ||
| Rate of administration | 1172 | ||
| Actions | 1173 | ||
| Indications and uses | 1173 | ||
| Contraindications | 1173 | ||
| Precautions | 1173 | ||
| Drug/lab interactions | 1173 | ||
| Side effects | 1173 | ||
| Antidote | 1173 | ||
| Trastuzumab | 1174 | ||
| Usual dose | 1174 | ||
| Dose adjustments | 1174 | ||
| Dilution | 1174 | ||
| Compatibility | 1175 | ||
| Rate of administration | 1175 | ||
| Actions | 1175 | ||
| Indications and uses | 1175 | ||
| Contraindications | 1175 | ||
| Precautions | 1176 | ||
| Drug/lab interactions | 1177 | ||
| Side effects | 1177 | ||
| Antidote | 1178 | ||
| Tromethamine | 1179 | ||
| Usual dose | 1179 | ||
| Pediatric dose | 1179 | ||
| Dose adjustments | 1179 | ||
| Dilution | 1179 | ||
| Compatibility | 1179 | ||
| Rate of administration | 1179 | ||
| Actions | 1179 | ||
| Indications and uses | 1179 | ||
| Contraindications | 1180 | ||
| Precautions | 1180 | ||
| Drug/lab interactions | 1180 | ||
| Side effects | 1180 | ||
| Antidote | 1180 | ||
| V | 1181 | ||
| Vaccinia immune globulin intravenous (human) | 1181 | ||
| Usual dose | 1181 | ||
| Dose adjustments | 1181 | ||
| Dilution | 1181 | ||
| Compatibility | 1181 | ||
| Rate of administration | 1181 | ||
| Actions | 1181 | ||
| Indications and uses | 1182 | ||
| Contraindications | 1182 | ||
| Precautions | 1182 | ||
| Drug/lab interactions | 1183 | ||
| Side effects | 1183 | ||
| Antidote | 1183 | ||
| Valproate sodium | 1184 | ||
| Usual dose | 1184 | ||
| Pediatric dose | 1184 | ||
| Dose adjustments | 1184 | ||
| Dilution | 1184 | ||
| Compatibility | 1184 | ||
| Rate of administration | 1184 | ||
| Actions | 1185 | ||
| Indications and uses | 1185 | ||
| Contraindications | 1185 | ||
| Precautions | 1185 | ||
| Drug/lab interactions | 1187 | ||
| Side effects | 1188 | ||
| Antidote | 1189 | ||
| Vancomycin hydrochloride | 1190 | ||
| Usual dose | 1190 | ||
| Pediatric dose | 1190 | ||
| Neonatal dose | 1191 | ||
| Dose adjustments | 1191 | ||
| Dilution | 1191 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1192 | ||
| Rate of administration | 1192 | ||
| Actions | 1192 | ||
| Indications and uses | 1193 | ||
| Contraindications | 1193 | ||
| Precautions | 1193 | ||
| Drug/lab interactions | 1193 | ||
| Side effects | 1194 | ||
| Antidote | 1194 | ||
| Vasopressin injection | 1195 | ||
| Usual dose | 1195 | ||
| All IV doses and uses are unlabeled. | 1195 | ||
| Treatment of shock-resistant VF or pulseless VT during cardiac arrest in adult patients: | 1195 | ||
| Hemodynamic support during vasodilatory shock (e.g., septic shock): | 1195 | ||
| Hypotension unresponsive to norepinephrine following cardiopulmonary bypass: | 1195 | ||
| GI hemorrhage: | 1195 | ||
| Pediatric dose | 1195 | ||
| Dilution | 1195 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1196 | ||
| Rate of administration | 1196 | ||
| Actions | 1196 | ||
| Indications and uses | 1196 | ||
| Contraindications | 1196 | ||
| Precautions | 1196 | ||
| Drug/lab interactions | 1197 | ||
| Side effects | 1197 | ||
| Antidote | 1197 | ||
| Vecuronium bromide | 1198 | ||
| Usual dose | 1198 | ||
| Pediatric dose | 1198 | ||
| Dose adjustments | 1198 | ||
| Dilution | 1198 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1198 | ||
| Rate of administration | 1199 | ||
| Actions | 1199 | ||
| Indications and uses | 1199 | ||
| Contraindications | 1199 | ||
| Precautions | 1199 | ||
| Drug/lab interactions | 1200 | ||
| Side effects | 1200 | ||
| Antidote | 1200 | ||
| Verapamil hydrochloride | 1201 | ||
| Usual dose | 1201 | ||
| Pediatric dose | 1201 | ||
| Dose adjustments | 1201 | ||
| Dilution | 1201 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1201 | ||
| Rate of administration | 1202 | ||
| Actions | 1202 | ||
| Indications and uses | 1202 | ||
| Contraindications | 1202 | ||
| Precautions | 1202 | ||
| Drug/lab interactions | 1203 | ||
| Side effects | 1204 | ||
| Antidote | 1204 | ||
| Verteporfin | 1204 | ||
| Usual dose | 1204 | ||
| Dose adjustments | 1205 | ||
| Dilution | 1205 | ||
| Compatibility | 1205 | ||
| Rate of administration | 1205 | ||
| Actions | 1205 | ||
| Indications and uses | 1205 | ||
| Contraindications | 1205 | ||
| Precautions | 1205 | ||
| Drug/lab interactions | 1206 | ||
| Side effects | 1207 | ||
| Antidote | 1207 | ||
| Vinblastine sulfate | 1208 | ||
| Usual dose | 1208 | ||
| Pediatric dose | 1208 | ||
| Dose adjustments | 1208 | ||
| Dilution | 1208 | ||
| Compatibility | 1208 | ||
| Rate of administration | 1209 | ||
| Actions | 1209 | ||
| Indications and uses | 1209 | ||
| Contraindications | 1209 | ||
| Precautions | 1209 | ||
| Drug/lab interactions | 1210 | ||
| Side effects | 1210 | ||
| Antidote | 1210 | ||
| Vincristine sulfate vincristine sulfate liposome injection | 1211 | ||
| Usual dose | 1211 | ||
| W | 1230 | ||
| Warfarin sodium | 1230 | ||
| Usual dose | 1230 | ||
| Pediatric dose | 1231 | ||
| Dose adjustments | 1231 | ||
| Dilution | 1231 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1231 | ||
| Rate of administration | 1231 | ||
| Actions | 1231 | ||
| Indications and uses | 1231 | ||
| Contraindications | 1232 | ||
| Precautions | 1232 | ||
| Drug/lab interactions | 1233 | ||
| Side effects | 1234 | ||
| Antidote | 1234 | ||
| Z | 1235 | ||
| Zidovudine | 1235 | ||
| Usual dose | 1235 | ||
| Pediatric dose | 1235 | ||
| Neonatal dose | 1235 | ||
| Dose adjustments | 1235 | ||
| Dilution | 1235 | ||
| Compatibility (underline indicates conflicting compatibility information) | 1236 | ||
| Rate of administration | 1236 | ||
| Actions | 1236 | ||
| Indications and uses | 1236 | ||
| Contraindications | 1236 | ||
| Precautions | 1236 | ||
| Drug/lab interactions | 1238 | ||
| Side effects | 1238 | ||
| Antidote | 1238 | ||
| Ziv-aflibercept | 1239 | ||
| Usual dose | 1239 | ||
| Dose adjustments | 1239 | ||
| Dilution | 1239 | ||
| Compatibility | 1240 | ||
| Rate of administration | 1240 | ||
| Actions | 1240 | ||
| Indications and uses | 1240 | ||
| Contraindications | 1240 | ||
| Precautions | 1240 | ||
| Drug/lab interactions | 1241 | ||
| Side effects | 1241 | ||
| Antidote | 1241 | ||
| Zoledronic acid | 1242 | ||
| Usual dose (international units [IU]) | 1242 | ||
| APPENDIX A Recommendations for the safe use and handling of cytotoxic drugs | 1251 | ||
| Introduction | 1251 | ||
| Potential routes of exposure | 1251 | ||
| Recommended practices for personnel preparing cytotoxic drugs | 1252 | ||
| Safe preparation of cytotoxic drugs | 1252 | ||
| Recommended practices for personnel administering parenteral cytotoxic drugs | 1253 | ||
| Appendix B FDA pregnancy categories | 1254 | ||
| APPENDIX D Information for patients receiving immunosuppressive agents | 1255 | ||
| APPENDIX E Recently approved drugs | 1256 | ||
| Prothrombin complex concentrate (human) | 1256 | ||
| Usual dose(international units [IU]) | 1256 | ||
| Dilution | 1256 | ||
| Compatibility | 1257 | ||
| Rate of administration | 1257 | ||
| Actions | 1257 | ||
| Indications and uses | 1258 | ||
| Contraindications | 1258 | ||
| Precautions | 1258 | ||
| Drug/lab interactions | 1259 | ||
| Side effects | 1259 | ||
| Antidote | 1259 | ||
| Index | 1261 | ||
| A | 1261 | ||
| B | 1267 | ||
| C | 1269 | ||
| D | 1271 | ||
| E | 1272 | ||
| F | 1273 | ||
| G | 1274 | ||
| H | 1274 | ||
| I | 1275 | ||
| J | 1276 | ||
| K | 1276 | ||
| L | 1276 | ||
| M | 1276 | ||
| N | 1277 | ||
| O | 1278 | ||
| P | 1279 | ||
| Q | 1280 | ||
| R | 1280 | ||
| S | 1281 | ||
| T | 1282 | ||
| U | 1283 | ||
| V | 1283 | ||
| W | 1284 | ||
| X | 1284 | ||
| Y | 1284 | ||
| Z | 1284 | ||
| Solution compatibility chart | ibc |